Design and application of protein nanoparticles

Abstract

The present invention describes protein nanoparticles containing a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide. In one embodiment, the nanoparticles comprise a diblock of repeating core polypeptides and repeating corona polypeptides, and one or more binding proteins. The nanoparticles can be used as therapeutic agents, target delivery agents, separation agents, or purification agents.

Description

[Technical Field]

[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 985,174, filed March 4, 2020, which is incorporated by reference herein in its entirety. Federally supported research This invention was made with United States government support under National Science Foundation Grant No. DMR-17-29671. The United States government has certain rights in this invention. Sequence Listing This application is filed in computer readable form of a sequence listing in accordance with 37 C.F.R. § 1.821(c). The text file submitted by EFS, "028193-9339-WO01_sequence_listing_2-MAR-2021_ST25.txt," was created on March 2, 2021, contains 121 sequences, has a file size of 294 kilobytes, and is incorporated herein by reference in its entirety.

[0002] Technical Field Described herein are protein nanoparticles comprising a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide. In one embodiment, the nanoparticles comprise a diblock of repeating core polypeptides and repeating corona polypeptides, and one or more binding proteins. The nanoparticles can be used as therapeutic agents, targeted delivery agents, separation agents, or purification agents. [Background technology]

[0003] In recent decades, there has been an explosion of interest in developing nanoparticle carriers for drug delivery, many of which are for the treatment of solid tumors. Many different types of nanoparticles, including inorganic nanoparticles (dendrimers), polymeric nanoparticles, and self-assembled nanostructures (micelles), as well as polymeric and lipid polymersomes / liposomes, have been synthesized and evaluated in preclinical models for cancer therapy. A general interest in this field is to achieve a figurative "magic bullet"—a drug that acts potently as intended without negative side effects. The challenge with this ideal is that most drugs must balance efficacy against delivery obstacles posed by human physiology. Nanoparticles have attracted much attention from the nanomedicine community because they could be the answer to this challenge for two reasons. First, they can be loaded with a wide range of small molecules with diverse physicochemical properties, making them near-universal carriers for small molecule drugs and diagnostic imaging agents. Second, properly designed nanoparticles exhibit good colloidal stability in the blood and can circulate for long periods of time. Therefore, the promise of nanocarriers lies in understanding how nanoscale material properties can alter the negative properties of developed drugs and confer them desirable properties. Other desirable properties may include resistance to drug clearance / degradation, tissue-specific targeting, increased cellular internalization, and increased solubility in serum.

[0004] Over the past two decades, many different drug delivery systems have emerged, and several have progressed into approved therapeutics today. The most widely used system is the liposome formulation, in which the liposome core is loaded with the drug, thus imparting the properties of the liposome formulation to the encapsulated cargo. Liposomes are excellent delivery vehicles due to their biocompatibility, ease of synthesis, and high loading capacity. However, for encapsulating more hydrophobic moieties, polymeric micellar systems are more advantageous because they are hydrophobic, have better morphology control, and have a larger volume / g compared to liposomes. However, challenges in synthesis, controlling the polydispersity of the assembled population, incorporating additional functionality, in vivo drug burst release, and overall biocompatibility limit their clinical potential.

[0005] The two terms "active" and "passive" targeting are commonly used in the literature. Passive targeting is enhanced by optimizing the shape, size, and surface charge of nanoparticles, resulting in improved tumor accumulation due to enhanced permeability and retention. Recently, high-aspect-ratio and highly flexible particles called filomicelles have attracted much research interest due to their long circulation time, high tumor penetration and accumulation, and enhanced active target delivery. These particles are produced via self-assembly or patterning, which are convenient for producing precise particle shapes, but are somewhat incompatible with the presentation of protein drugs or protein targeting ligands because the conditions used for their synthesis can denature proteins, rendering them inactive in the body.

[0006] Passive targeting is a useful approach for local targeting of solid tumors, but it does not directly target tumor cells, which are the ultimate destination of drugs or imaging agents. The rationale for creating targeted nanoparticles for cancer therapy or imaging stems from the fact that many tumors have surface proteins that are overexpressed or, in some cases, uniquely expressed on the surface of tumor cells compared to normal, healthy cells. Homed nanoparticles to tumor cells by decorating them with ligands specific for tumor-selective or tumor-specific markers can provide a second step in tumor cell-specific targeting if the carrier accumulates to a sufficiently high concentration in the local tumor environment.

[0007] Active targeting utilizes specific binding motifs and targeting structures on cells of interest to localize particles loaded with drugs or imaging agents bearing biophysical signals. A common approach to synthesizing targeted nanocarriers is to covalently functionalize the surface of nanoparticles with peptides or proteins. However, this approach has limited control over ligand titer and typically requires excess ligand to drive the reaction. Therefore, scale-up is expensive, and quality control and product validation remain significant challenges. What is needed are fusion proteins that can form nanoparticles for cell targeting, drug delivery, and biomolecule purification. Summary of the Invention

[0008] One embodiment described herein is a composition comprising a protein nanoparticle comprising a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide. In one aspect, the fusion protein comprises multiple unstructured polypeptides. In another aspect, the fusion protein comprises multiple targeting polypeptides. In another aspect, the unstructured polypeptide comprises a diblock peptide. In another aspect, the unstructured polypeptide comprises a diblock of a core polypeptide and a corona polypeptide. In another aspect, the unstructured polypeptide comprises a core n -corona m where n is a repetition number of 20 to 200, and m is a repetition number of 40 to 200. In another embodiment, the core polypeptide comprises the sequence QYPSDGRG (SEQ ID NO:1), GRGDQPYQ (SEQ ID NO:2), GRGDSPYQ (SEQ ID NO:3), GRGDSPYS (SEQ ID NO:4), GRGDQPYS (SEQ ID NO:5), GRGDSP[3Y:V]S (SEQ ID NO:6), GRGDSP(Y:V]S (SEQ ID NO:7), or a combination thereof. In another embodiment, the corona polypeptide comprises the sequence VPG[A:G]G (SEQ ID NO:8), VPGSG (SEQ ID NO:9), VPGVG (SEQ ID NO:10), VPQQG (SEQ ID NO:11), GRGDSPAS (SEQ ID NO:12), GRGDSPIS (SEQ ID NO:13), GRGDSPVS (SEQ ID NO:14), GRGDQPHN (SEQ ID NO:15), GRGDNPHQ (SEQ ID NO:16), GRGDSPV (SEQ ID NO:17), or a combination thereof. In another embodiment, the core polypeptide comprises the sequence (RLP) n(SEQ ID NO: 1), where n is the number of repeats between 20 and 200. In another embodiment, the corona polypeptide comprises the sequence (ELP)m (SEQ ID NO: 8), where m is the number of repeats between 40 and 200. In another embodiment, the diblock comprises RLP40-ELP40 (SEQ ID NO: 83), RLP40-ELP80 (SEQ ID NO: 84), RLP40-ELP160 (SEQ ID NO: 82), RLP60-ELP80 (SEQ ID NO: 85), RLP80-ELP80 (SEQ ID NO: 87), RLP80-ELP160 (SEQ ID NO: 86), or RLP100-ELP80 (SEQ ID NO: 88). In another embodiment, the targeting polypeptide comprises a polypeptide between 2 kDa and 100 kDa. In another embodiment, the targeting polypeptide comprises a type III domain from human fibronectin (Fn3) (SEQ ID NO: 60), an aFn3 domain from human tenascin-C (Tn3) (SEQ ID NO: 62), or a Z domain of staphylococcal protein A (SEQ ID NO: 64). In another embodiment, the targeting polypeptide comprises a type III domain from human fibronectin (Fn3) (SEQ ID NO: 60). In another embodiment, the targeting polypeptide comprises an Fn3 domain from human tenascin-C (Tn3) (SEQ ID NO: 62). In another embodiment, the targeting polypeptide comprises a Z domain of staphylococcal protein A having a sequence comprising (SEQ ID NO: 64). In another embodiment, the core polypeptide is cross-linked.

[0009] Another embodiment described herein is a protein nanoparticle comprising a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide. In one aspect, the fusion protein comprises multiple unstructured polypeptides. In another aspect, the fusion protein comprises multiple binding polypeptides. In another aspect, the unstructured polypeptide comprises a diblock peptide. In another aspect, the unstructured polypeptide comprises a diblock of a core polypeptide and a corona polypeptide. In another aspect, the unstructured polypeptide comprises a core polypeptide. n -corona mwherein n is the number of repeats from 20 to 200 and m is the number of repeats from 40 to 200. In another embodiment, the core polypeptide comprises the sequence QYPSDGRG (SEQ ID NO: 1), GRGDQPYQ (SEQ ID NO: 2), GRGDSPYQ (SEQ ID NO: 3), GRGDSPYS (SEQ ID NO: 4), GRGDQPYS (SEQ ID NO: 5), GRGDSP[3Y:V]S (SEQ ID NO: 6), GRGDSP(Y:V]S (SEQ ID NO: 7), or a combination thereof. In another embodiment, the repeating core polypeptide sequence comprises a sequence selected from the group consisting of azidophenylalanine, acetylphenylalanine, propargyloxyphenylalanine, acetylphenylalanine, or azidohomoalanine. At least 1-10 selected non-canonical amino acids are interspersed. In another embodiment, the corona polypeptide comprises the sequence VPG[A:G]G (SEQ ID NO:8), VPGSG (SEQ ID NO:9), VPGVG (SEQ ID NO:10), VPQQG (SEQ ID NO:11), GRGDSPAS (SEQ ID NO:12), GRGDSPIS (SEQ ID NO:13), GRGDSPVS (SEQ ID NO:14), GRGDQPHN (SEQ ID NO:15), GRGDNPHQ (SEQ ID NO:16), GRGDSPV (SEQ ID NO:17), or a combination thereof. In another embodiment, the core polypeptide comprises the sequence (RLP) n(SEQ ID NO: 1), where n is the number of repeats between 20 and 200. In another embodiment, the corona polypeptide comprises the sequence (ELP)m (SEQ ID NO: 8), where m is the number of repeats between 40 and 200. In another embodiment, the diblock comprises RLP40-ELP40 (SEQ ID NO: 83), RLP40-ELP80 (SEQ ID NO: 84), RLP40-ELP160 (SEQ ID NO: 82), RLP60-ELP80 (SEQ ID NO: 85), RLP80-ELP80 (SEQ ID NO: 87), RLP80-ELP160 (SEQ ID NO: 86), or RLP100-ELP80 (SEQ ID NO: 88). In another embodiment, the targeting polypeptide comprises a polypeptide between 2 kDa and 100 kDa. In another embodiment, the binding polypeptide comprises a type III domain from human fibronectin (Fn3) (SEQ ID NO: 60), aFn3 domain from human tenascin C (Tn3) (SEQ ID NO: 62), or the Z domain of Staphylococcus aureus protein A (SEQ ID NO: 64). In another embodiment, the binding polypeptide comprises a type III domain from human fibronectin (Fn3) (SEQ ID NO: 60). In another embodiment, the binding polypeptide c comprises an Fn3 domain from human tenascin C (Tn3) (SEQ ID NO: 62). In another embodiment, the binding polypeptide comprises a Z domain of Staphylococcus aureus protein A having a sequence comprising (SEQ ID NO: 64). In another embodiment, the core is covalently crosslinked using photo or other click chemistry compatible linkers. In another embodiment, the core polypeptide is crosslinked. In another embodiment, the nanoparticle encapsulates one or more small molecule drugs therein. In another embodiment, the fusion protein further comprises a therapeutic protein. In another embodiment, the composition is a therapeutic agent, a targeted delivery agent, a separation agent, or a purification agent. In another embodiment, the binding polypeptide comprises an ErbB2 receptor binding protein (ANHP) (SEQ ID NO: 74). In another embodiment, the binding polypeptide comprises a cell-binding peptide (GRGDSPAS) (SEQ ID NO: 76). In another embodiment, the binding polypeptide comprises an adeno-associated virus (AAV) binding protein (PKD2) (SEQ ID NO: 112). In another embodiment, the binding polypeptide comprises an adenovirus (AdV) binding protein (CAR) (SEQ ID NO: 114).In another embodiment, the binding polypeptide comprises lentivirus (LV) binding protein (CR2) (SEQ ID NO: 116) or (CR3) (SEQ ID NO: 118). In another embodiment, the binding polypeptide comprises albumin binding protein (ABP) (SEQ ID NO: 120).

[0010] Another embodiment described herein is a therapeutic agent comprising the protein nanoparticles described herein. Another embodiment described herein is a method of targeting a therapeutic agent to a cell, comprising administering a protein nanoparticle described herein. Another embodiment described herein is a method of delivering a therapeutic agent to a cell, comprising administering a protein nanoparticle described herein.

[0011] Another embodiment described herein is a means for targeting a therapeutic agent to a cell, comprising administering a protein nanoparticle described herein. Another embodiment described herein is a means for delivering a therapeutic agent to a cell, comprising administering a protein nanoparticle described herein. Another embodiment described herein is a method for identifying a biomolecule, comprising administering a protein nanoparticle described herein that binds to the biomolecule.

[0012] Another embodiment described herein is a method for purifying a biomolecule, comprising isolating the biomolecule from a culture medium using the protein nanoparticles described herein that bind to the biomolecule. In another aspect, the method further comprises triggering phase separation of the binding polypeptide to isolate the biomolecule from the contaminant, wherein the trigger is selected from adjusting temperature, salt, light, pH, pressure, the concentration of the binding polypeptide or the concentration of the biomolecule, applying electromagnetic or acoustic waves, or adding one or more excipients, including one or more of a cofactor, a surfactant, a crowding agent, a reducing agent, an oxidizing agent, a denaturant, or an enzyme. In another aspect, the method further comprises using centrifugation to separate the densely phase-separated protein bound to the biomolecule from the contaminating biomolecule. In another aspect, the method further comprises using centrifugation to separate the phase-separated protein bound to the biomolecule from the contaminating biomolecule. In another aspect, the method further comprises using the size of the phase-separated droplets to isolate the biomolecule from the contaminant, wherein the size of the binding polypeptide bound to the biomolecule is at least 20 nm and no more than 100 μm in diameter. In another aspect, the method comprises isolating biomolecule-binding polypeptide complexes from contaminant species based on size using flow filtration, membrane chromatography, analytical ultracentrifugation, high performance liquid chromatography, membrane chromatography, normal flow filtration, sonic separation, centrifugation, counterflow centrifugation, and fast protein liquid chromatography.

[0013] Another embodiment described herein is a biomolecule comprising at least one of a lipid, a cell, a protein, a nucleic acid, a carbohydrate, or a viral particle, wherein the nucleic acid is single-stranded or double-stranded DNA or RNA, the viral particle is selected from an adenovirus particle, an adeno-associated virus particle, a lentivirus particle, a retrovirus particle, a poxvirus particle, a measles virus particle, or a herpesvirus particle, and the protein is selected from human albumin, a monoclonal IgG antibody, or an Fc-fusion antibody.

[0014] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief explanation of the drawings]

[0015] [Figure 1] Figure 1 shows the main parameters that influence the fate of nanoparticles in vivo. [Figure 2A-C] Figures 2A–C show the predicted equilibrium morphologies of AB diblock polymers in the bulk. Figure 2A shows S and S′ = body-centered cubic spheres, C and C′ = hexagonally packed cylinders, G and G′ = bicontinuous gyroids, and L = lamellae. Figure 2B shows the theoretical phase diagram of the AB diblock predicted by self-consistent mean-field theory as a function of the block volume fraction (f) and the separation parameter χN, where w is the Flory-Huggins intersegment interaction energy, N is the degree of polymerization, and CPS and CPS′ = close-packed spheres. Figure 2C shows the experimental phase diagram of polyisoprene-block-polystyrene copolymers, where fA represents the volume fraction of polyisoprene and PL = perforated lamellae. [Figure 3] FIG. 3 shows SDS-PAGE of the RLP-ELP protein. 1. RLP20-ELP80 (SEQ ID NO: 81), 2. RLP40-ELP80 (SEQ ID NO: 84), 3. RLP60-ELP80 (SEQ ID NO: 85), 4. RLP80-ELP80 (SEQ ID NO: 87), 5. RLP100-ELP80 (SEQ ID NO: 88), 6. RLP40-ELPS80 (SEQ ID NO: 89), 7. RLP80-ELPS80 (SEQ ID NO: 91), 8. RLP40-ELPV80 (SEQ ID NO: 92), 9. RLP80-ELPV80 (SEQ ID NO: 94), 10. RLP20-ELP40 (SEQ ID NO: 80), 11. RLP40-ELP40 (SEQ ID NO: 83), 12. RLP40-ELP160 (SEQ ID NO: 82), 13. RLP80-ELP160 (SEQ ID NO: 86). [Figure 4]Figure 4 shows cryo-TEM images of the RLPXX-ELP80 (SEQ ID NOs: 84, 85, 87) block copolypeptide. Decreasing the size of the core block, thereby increasing the overall hydrophilic mass fraction, shifts the self-assembly from worm-like to spherical. Data were collected at 10 μM in 140 mM PBS. Scale bar = 500 nm. [Figure 5] Figure 5 shows cryo-TEM images of RLP40-ELP80 (SEQ ID NO: 84) at increasing volume fractions, which does not appear to affect the observed aggregation state. Data were collected at 10, 100, and 1000 μM, respectively, in 140 mM PBS. Scale bar = 500 nm. [Figure 6] Figure 6 shows cryo-TEM images of RLPXX-ELPY block copolypeptides (SEQ ID NOs: 80-87). Data were collected at 10 μM in 140 mM PBS. Scale bar = 500 nm. [Figure 7] Figure 7 shows cryo-TEM images of RLPXX-ELPSYY (SEQ ID NOs: 89-91) and RLPXX-ELPVYY (SEQ ID NOs: 92-94) block copolypeptides. Data were collected at 10 μM in 140 mM PBS. Scale bar = 500 nm. [Figure 8] Figure 8 shows cryo-TEM images of RLP-ELP block copolypeptides with varying core hydrophobicity. Scale bar = 500 nm. Data were collected at 1 mg mL in 140 mM PBS. [Figure 9] Figure 9 shows cryo-TEM images of the (GRGDSP[Y:V]S)-ELP (SEQ ID NO: 110) block copolypeptide in 140 mM PBS and distilled HO. Data were collected at 1 mg mL and 15 °C. [Figure 10] FIG. 10 shows fluorescence measurements of the pyrene peaks (I1 and I3) in various concentrations of the RLPXX-ELP80 (SEQ ID NOs: 84, 86) block copolypeptide in 140 mM PBS at 20° C. [Figure 11]Figure 11 shows cryo-TEM images of RLP40-ELP80 block copolypeptides whose core sequences contain various amounts of Ser and Glu. Data were collected at 1 mg mL in 140 mM PBS at 15 °C. [Figure 12] FIG. 12 is a schematic diagram of the paclitaxel loading and analysis procedure for RLP40-ELP80 (SEQ ID NO: 84) micelles. [Figure 13] Figure 13 shows the relative molar ratios of paclitaxel (PTX) to RLP-ELP as determined by analytical high-performance liquid chromatography. The absorption peaks of each molecule (230 nm for PTX and 275 nm for RLP-ELP80) were used to derive the area of ​​each molecule, which were then normalized to the extinction coefficients of the molecules and compared to each other. [Figure 14] Figure 14 shows SDS-PAGE of RLPXX-ELP80-Fn3 (SEQ ID NOs: 95-97). The ladder is in kilodaltons. Wells are labeled with the appropriate protein in the gel. All constructs exhibit a band approximately twice the molecular weight of the main band in the presence of gel loading buffer, likely indicating dimer formation. With the exception of this band, all material is greater than 95% pure. [Figure 15] Figure 15 shows the thermal stability of RLP-ELP-Fn3 micelles. The stability of spherical (RLP40-ELP80-Fn3) (SEQ ID NO: 96) and worm-like micelles (RLP80-ELP80-Fn3) (SEQ ID NO: 97) was measured between room temperature (20°C) and physiological temperature (37°C). Data were collected at 10 μM in 140 mM PBS. Filtered through a 0.45 μm filter. [Figure 16] Figure 16 shows the thermal stability of block copolypeptide micelles. The stability of spherical (RLP40-ELP80) (SEQ ID NO: 84) and worm-like micelles (RLP80-ELP80) (SEQ ID NO: 87) was measured between room temperature (20°C) and physiological temperature (37°C). Data were collected at 10 μM in 140 mM PBS. Filtered through a 0.45 μm filter. [Figure 17A-D]Figures 17A-D show raw static and dynamic light scattering data for RLP-ELP block copolypeptides. Plots of Rh versus angle, extrapolated to 0° for the reported Rh, are shown in Figure 17A: RLP20-ELP80-Fn3 (SEQ ID NO: 95), Figure 17B: RLP40-ELP80-Fn3-10 (SEQ ID NO: 96), and Figure 17C: RLP80-ELP80-Fn3 (SEQ ID NO: 97). Figures 17D-E show partial Zimm plots obtained by static light scattering. Figure 17D: RLP40-ELP80-Fn3 (SEQ ID NO: 96), Figure 17E: RLP80-ELP80-Fn3 (SEQ ID NO: 97). [Figures 18A-D] Figures 18A-D show cryo-TEM micrographs of RLPXX-ELP80 and RLPXX-ELP80-Fn3. Figure 18A shows spherical micelles formed by RLP40-ELP80 (SEQ ID NO: 84). Figure 18B shows worm-shaped micelles formed by RLP80-ELP80 (SEQ ID NO: 87), and Figure 18C shows spherical micelles formed by RLP40-ELP80-Fn3 (SEQ ID NO: 96). Figure 18D shows spherical and worm-shaped and spherical micelles formed by RLP80-ELP80-Fn3 (SEQ ID NO: 97). All scale bars represent 200 nm. All data were collected at 10 μM in 140 mM PBS at 15 °C. [Figure 19] Figure 19 shows a histogram of observed aspect ratios of RLPXX-ELPYY-Fn3 (SEQ ID NOS: 95-97). Data from Figure 18, specifically the longest straight line and corresponding vertical measurements of individual particles, were used to describe the observed particle aspect ratios. Only particles that were clearly individual particles were used for analysis (equal contrast around the particle suggests normal camera orientation). n=50. [Figure 20]Figure 20 shows the shape-dependent avidity of RLPXX-ELP80-Fn3 (SEQ ID NOs: 95-97). Multivalency increases the observed KD, as does the aspect ratio of the micelles. Representative SPR sensorgrams shown at the top demonstrate a significant decrease in koff between unimers and spherical and wormlike micelles. In contrast, koff is similar for all constructs of interest. SPR sensorgram data were collected at 10 μM in PBS. [Figure 21A-B] Figures 21A-B show the cellular uptake of undecorated block copolypeptides. Figure 21A shows a representative image of the cellular uptake of the Fn3 domain-free RLPXX-ELP80 (SEQ ID NOs: 81, 84, 87) block copolypeptide labeled with an Alexa488 fluorophore (green) overlaid on a DIC image (gray) after 2.5 hours of incubation at 10 μM in serum-free minimal medium. Scale bar = 20 μm. Figure 21B shows quantification of intracellular particle numbers from confocal microscopy images. n>100, *=p<0.05, **=p<0.01, ***=p<0.001. [Figure 22] Figure 22 shows a representative image of cellular uptake of RLPXX-ELP (SEQ ID NOs: 84, 87) block copolypeptides labeled with Alexa488 fluorophore (green) overlaid on a DIC image (gray) after 2.5 hours of incubation at 10 μM in serum-free minimal medium. Scale bar = 20 μm. [Figure 23A-D] Figure 23A-D shows the cellular uptake of RLPXX-ELPYY-Fn3 (SEQ ID NOs: 95-97) polypeptides in the αvβ3-negative K562 cell line. A-D are representative images of cellular uptake of blocking polypeptides labeled with the Alexa488 fluorophore (green) overlaid on DIC images (gray) after 2.5 hours of incubation at 10 μM in serum-free minimal medium. A. LM609 antibody; B. RLP20-ELP80-Fn3 (SEQ ID NO: 95), C. RLP40-ELP80-Fn3 (SEQ ID NO: 96), D. RLP80-ELP80-Fn3 (SEQ ID NO: 97). Scale bar = 20 μm. [Figure 24]FIG. 24 shows flow cytometry data for naive cells, LM609 antibody, RLP40-ELP80-Fn3 (SEQ ID NO: 96)-spherical micelles, and RLP80-ELP80-Fn3 (SEQ ID NO: 97)-worm-like micelles. [Figure 25] Figure 25 shows quantification of cellular uptake by flow cytometry. ***=p<0.001. Boxes indicate the 25th and 75th percentiles, bars indicate the 10th and 90th percentiles. [Figure 26A-D] Figure 26A-D shows the cellular uptake of RLPXX-ELPYY-Fn3 (SEQ ID NOs: 96-99) polypeptides with variable aspect ratios in αvβ3-transfected cell lines. A-D are representative images of cellular uptake of blocking polypeptides labeled with the Alexa488 fluorophore (green) overlaid on DIC images (gray) after 1.5 h incubation at 10 μM in serum-free minimal medium. A. RLP80-ELP80-Fn3 (SEQ ID NO: 97); B. RLP80-ELP160-Fn3 (SEQ ID NO: 98); C. RLP40-ELP80-Fn3 (SEQ ID NO: 96); D. RLP40-ELP40-Fn3 (SEQ ID NO: 99). Relative to particles with elongated morphology (A, D), the level of uptake of all constructs with spherical morphology (B, C) is much lower. Scale bar = 20 μm. [Figure 27A-B] Figures 27A-B show cryo-TEM characterization of "shape-controlled" RLPXX-ELPYY-Fn3. A. Spherical micelles formed by RLP80-ELP160-Fn3 (SEQ ID NO: 98), B. Spherical and worm-like micelles formed by RLP40-ELP80-Fn3. All data were collected at 10 µM in 140 mM PBS at 15 °C. [Figure 28] Figure 28 shows the cellular uptake of block copolypeptides over time. Representative confocal images of antibody (LM609), RLP20-ELP80-Fn3 (SEQ ID NO: 95), RLP40-ELP80-Fn3 (SEQ ID NO: 99), and RLP80-ELP80-Fn3 (SEQ ID NO: 97) uptake as a function of time. Scale bar = 20 μm. [Figure 29A-B]Figures 29A-B show quantification of cellular uptake by image analysis. Figure 29A shows quantification of the number of intracellular particles over time. Figure 29B shows quantification of the area of ​​intracellular particles over time. *=p<0.05, **=p<0.01, ***=p<0.001. Error bars represent standard deviation. [Figure 30A-D] Figures 30A-D. A. Cryo-TEM image of [S]-40-[QHN]-40 (SEQ ID NO: 100). Scale bar: 500 nm. B. Cryo-TEM image of [S]-80-[QHN]-40 (SEQ ID NO: 101). Scale bar: 500 nm. C. Cryo-TEM image of [S]-40-[QHN]-40 (SEQ ID NO: 100). Scale bar: 200 nm. D. Cryo-TEM image of [S]-80-[QHN]-40 (SEQ ID NO: 101). Scale bar: 200 nm. All constructs were vitrified at 2 mg mL in 140 mM PBS, 100% humidity, and 37 °C. [Figure 31A-B] Figures 31A-B. Figure 31A shows the UCST phase behavior of the [S]-40-[QHN]-40 (SEQ ID NO: 100) and [S]-80-[QHN]-40 (SEQ ID NO: 101) block copolypeptides, as determined by UV-visible spectrophotometry. Figure 31B shows the effect of pH on the UCST behavior of the RLP-RLP block copolypeptides, as observed via temperature-dependent DLS. Data obtained at 2 mg mL in 140 mM PBS show that the UCSTs of both block copolypeptides are very similar, and thus, similar pH-induced UCST deflections are observed. [Figure 32A-B] Figure 32A shows the critical micelle concentration (CMC) of [S]-40-[QHN]-40 (SEQ ID NO: 100) and [S]-80-[QHN]-40 (SEQ ID NO: 101), determined to be 3 μM and 0.4 μM, respectively, due to the shift in I / I of pyrene fluorescence. A sigmoidal fit to split the data into thirds is shown. The CMC is determined by the inflection point of the sigmoidal fit. Figure 32B shows the complete thermal characterization of [S]-40-[QHN]-40 and (SEQ ID NO: 100)[S]-80-[QHN]-40 (SEQ ID NO: 101), demonstrating that increasing the core block shifts the behavior of the decomposed UCST phase. [Figure 33A-B]33A-B show UV-visible spectrophotometry and dynamic light scattering of the [S]-40-[V]-40 (SEQ ID NO: 105) and [S]-40-[Y:3V]-40 (SEQ ID NO: 104) block copolypeptides. [Figure 34] Figure 34 shows cryo-TEM images of [S]-40-[V]-20 (SEQ ID NO: 105), [S]-40-[V]-40 (SEQ ID NO: 106), and [S]-40-[V]-60 (SEQ ID NO: 107). Data were collected in 140 mM PBS at 15°C. Scale bar = 500 nm. [Figure 35] Figure 35 shows cryo-TEM images of [S]-40-[A]-40 (SEQ ID NO: 108), [S]-40-[V]-40 (SEQ ID NO: 106), and [S]-40-[I]-40 (SEQ ID NO: 109). Data were collected in 140 mM PBS at 15°C. Scale bar = 500 nm. [Figure 36] Figure 36 shows a comparison of the stability of the two pAzF-containing sphere-forming diblock constructs investigated in this study. The constructs were mixed with pAzF-free DB-40 diblock at different ratios, cross-linked at 7 μM, and their hydrodynamic radii were recorded using DLS at 700 nM in 7.2 M GuHCl. Note that both pAzF constructs were unable to form stable cross-linked particles when the pAzF-to-polypeptide ratio was below 1. [Figure 37A-C] Figures 37A-C show cryo-TEM analysis of the pAzF-containing constructs UAA5-40 and UAA4-80. Figure 37A shows the presence of visible particles in GuHCl, demonstrating successful crosslinking for the UAA5-40 construct. The scale bar represents 100 nm. Figure 37B shows image analysis of the core radius of UAA5-40 particles, which showed significant swelling after GuHCl exposure. Particles appear small because only the collapsed RLP core possesses electron density high enough for TEM. 100 particles were measured per condition. Figure 37C shows that the UAA4-80 construct existed as highly elongated, flexible worms after crosslinking that retained their morphology, even in the presence of GuHCl. The scale bar represents 300 nm. [Figure 38A-B]Figures 38A-B show CAC determinations of both sphere- and worm-forming constructs using DLS. While the crosslinked sample showed stable nanoparticle measurements down to the low nanomolar range, the estimated limit of detection for the DLS instrument, all other samples appeared to degrade above that threshold. Overall, the worm-forming constructs (Figure 38B) had lower CAC than their globular analogs (Figure 38A), and constructs containing pAzF were similar compared to the analogous non-pAzF-containing polypeptides. Note that all samples were prepared in PBS, and error bars represent standard deviations over 20 measurements. [Figure 39A-B] Figures 39A-B show the SDS-PAGE gel (Figure 39A) and protein yield (Figure 39B) after expression and purification of all UAA5-40-K8D4-ligand constructs in this study. Note that all lanes display target mass bands, except for the TRAIL sample (pink). Also note that both the AHNP and TRAIL peptide ligands contain cysteine ​​residues, as a faint band corresponding to the dimer is visible in the SDS-PAGE gel. [Figure 40A-B] Figures 40A-B show cell viability assays testing the cytotoxicity of Polyvia-MPI, Tn3, and TRAIL peptide ligands. All ligands were tested against crosslinked UAA5-40 nanoparticles and co-incubated with Colo205 (ligand is either Tn3 or TRAIL peptide) and K562 cells (ligand is Polyvia-MPI) for 24 hours, respectively. [Figure 41] Figure 41 shows confocal images of a cellular uptake study of the breast cancer cell line SK-BR-3 using crosslinked UAA5-40-K8D4-ligand nanoparticles at a concentration of 7 μM. All ligands except the Fn3 scaffold showed a significant increase in cellular uptake compared to the non-functionalized control. Theoretically, this effect was expected only for the AHNP ligand, as it targets the ErbB2 receptor on SK-BR-3 cells. Due to cell adhesion on the plate, brightfield contrast is very poor; however, note that there are approximately 20 cells in each image. The scale bar represents 30 μm. [Figure 42A-B] Figures 42A-B show confocal images of native and αvβ3-transfected K562 cells after co-incubation with AF488-tagged crosslinked UAA5-40-K8D4-ligand nanoparticles. Scale bars represent 20 μm. Figure 42A shows the cellular uptake of the sphere-forming ELP / RLP diblock construct over CAC. Comparison of the native and αvβ3-transfected cell lines indicates that the increased uptake observed for the Fn3 and GRGDSPAS ligands was caused by integrin presentation on the cell membrane. Note that cellular uptake was not homogenous across populations due to previously reported variations in integrin expression levels in this cell line. Polyvia-MPI, on the other hand, showed increased uptake in both cell lines, but more so in the native variant. Figure 42B shows a similar experiment at concentrations below the CAC of the ELP / RLP carrier, demonstrating that both the Fn3- and GRGDSPAS-constructs, but not the Polyvia-MPI construct, still had increased cellular uptake compared to the non-functionalized control. Note that the brightness of these images has been adjusted compared to Figure 42A due to the overall reduced uptake levels. [Figure 43A-F] Figures 43A–F show the characterization of three different UAA4-80-K8D4-ligand constructs using DLS (Figure 43A) and TEM (Figures 43B–E). Functionalization of the UAA4-80 constructs had a substantial effect on particle morphology after crosslinking. Although spherical structures were also observed for the non-functionalized UAA4-80 construct (Figure 43E), they were only minor by-products. However, the functionalized constructs exclusively formed this type of structure. Figure 42F shows the cryo-TEM core radius as measured via Image J. Note that all samples were crosslinked at 7 μM. All scale bars represent 200 nm. [Figure 44A-F]Figures 44A-F show the characterization of the functionalized UAA4-80 construct after removal of the K8D4-linker. Both DLS (Figure 44A) and cryo-TEM (Figures 44B-E) showed that the nanoparticles obtained after crosslinking still had a spherical morphology, rather than an elongated worm-like shape. Characterization of the UAA4-80-K8D4 construct (Figures 44A, E, F) nevertheless showed that attachment of the linker alone also resulted in a spherical morphology. Note that all samples were crosslinked at 7 μM. All scale bars represent 200 nm. [Figure 45A-B] Figures 45A-B show cell viability plots comparing the potency of the crosslinked constructs UAA5 (Figure 45A) and UAA4 (Figure 45B) with and without the K8D4 linker. In addition to the strong increase in potency upon linker introduction, the plots also showed that the K8D4-containing construct with the smaller UAA5-40 base was significantly more potent. [Figure 46A-B] Figure 46A shows a direct comparison of similar constructs in their native and cross-linked states, clearly demonstrating that cross-linking increased the potency of each nanoformulation by several orders of magnitude. Figure 46B shows a comparison of cell viability curves with CAC data for both the pAzF-free and pAzF-containing diblocks, demonstrating that the determined EC50 values ​​were in near perfect agreement with the CAC of the pAzF-free DB-40 / 80 construct. Thus, particle degradation below the CAC appears to be the limiting factor for loosely self-assembled nanoparticles in terms of efficacy. [Figure 47] Figure 47 shows a comparison of the cytotoxicity of crosslinked UAA5-40 nanoparticles with different degrees of Tn3 functionalization. The nanoparticles could tolerate partial functionalization up to at least 50% without a significant loss of efficacy. [Figure 48A-C]Figure 48A shows flow cytometry data for the two K562 cell lines used in this study after 90 minutes of co-incubation with either PBS or 350 nM of anti-αvβ3 antibody. Note that a secondary subpopulation with significantly increased fluorescence is observed in the transfected cell line. This subpopulation accounts for 12.6% of all analyzed cells. Figures 48B-C. Based on the observations in A, we decided to focus only on the most strongly fluorescent 10% of the total cell population, allowing for more clearly differentiated two cell lines in box plots. In the "Full Range" plot (Figure 48B), boxes represent the 25th and 75th percentiles, and bars represent the 10th and 90th percentiles. In the "Top 10 Percent" plot (Figure 48C), boxes represent the 93rd / 97th percentiles, and bars represent the 91st / 99th percentiles. [Figure 49A-B] Figures 49A-B show flow cytometry data from a cellular uptake experiment comparing UAA5 (Figure 49A) and UAA4 (Figure 49B), two different K562 cell lines in this study. All cells were co-incubated with crosslinked AF488-tagged nanoparticles for 90 minutes. Only particles carrying Fn3 and GRGDSPAS ligands showed selective uptake for the αvβ3-presenting cell line. Boxes in the box plot diagram represent the 93rd and 97th percentiles, and bars represent the 91st and 99th percentiles. [Figure 50A-B] Figure 50A-B shows flow cytometry data for multivalent experiments with αvβ3-transfected K562 cells. For both diblock architectures, crosslinking significantly increased the cellular uptake of Fn3- and GRGDSPAS-decorated nanoparticles in the sub-CAC regime. Note that the selected concentration of the UAA4-80 construct was a compromise between its CAC (approximately 30-50 nM) and the detection limit of the assay (approximately 10 nM). Therefore, the improvement upon crosslinking was less significant for the UAA4-80 (B) construct, as well as for the UAA5-40 (A) diblock. In the box plot diagram, boxes represent the 93rd and 97th percentiles, and bars represent the 91st and 99th percentiles. [Figure 51A-C] Figures 51A-C show SPR analysis of αvβ3 integrin binding of the UAA5-40 diblock construct. Figure 51A. In the crosslinked state, Fn3- and GRGDSPAS-functionalized particles exhibited very high binding affinity for αvβ3 integrin. In comparison, Dzuricky et al.'s native Fn3 construct had a reported KD of 79 nM. Figure 51B. In the native state, the GRGDSPAS construct showed no binding at concentrations below the CAC. Meanwhile, binding was observed at lower levels for these native Fn3 analogs than for the crosslinked nanoparticles. Figure 51C. At concentrations above the CAC, the native and crosslinked constructs exhibited comparable binding affinity for αvβ3 integrin. Note that the vertical dotted line indicates the buffer exchange point. [Figure 52A-C] Figures 52A-C show SPR characterization of integrin-targeting UAA4-80 constructs. Figure 52A. The GRGDSPAS-functionalized construct appeared to have a sharp cutoff for binding to αβ3 integrin, as the SPR signal dropped rapidly upon dilution below 150 nM. Figure 52B. For the Fn3-functionalized construct, the SPR data were more confounding, showing good binding at 68 nM but no binding at concentrations above or below that value. Figure 52C. Thus, the only KD value that could be calculated was for the crosslinked GRGDSPAS construct over a narrow concentration range of approximately 170 nM. Note that the vertical dotted line indicates the point where the buffer was exchanged. [Figure 53A-B] Figures 53A-B show SPR characterization of the DR5-targeted UAA5-40 construct. Comparison of the SPR data in Figures 53A and 53B indicated that the binding affinity of the Tn3-ligand appears to benefit little from multivalent presentation compared to the integrin-targeted construct in Figure 52. This, in turn, indicated that the requirement for multivalency for Tn3 action stems primarily from downstream effects after receptor binding, and not from DR5 binding itself. Note that the vertical dotted lines indicate the points where buffer was exchanged during the SPR experiments. [Figure 54]Figure 54 shows an SDS-PAGE image of the capture and release of an antibody therapeutic from cell culture harvest. The diblock material elutes a purer mAb product than the single-chain ELP unimer. Comparison of the eluted final product is between wells 2-11, 4-13, and 6-15. [Figure 55] Figure 55 shows example purity data for producing proteins containing unnatural amino acids that can then be crosslinked into nanoparticle structures. This method is applicable to a variety of ligand sizes and architectures and can be produced in high purity using the simple purification scheme described herein. [Figure 56] Figure 56 shows the cellular uptake of cross-linked polypeptide scaffolds with various protein domains at the corona of nanoparticles. Proteins are labeled with green fluorescent molecules for visualization. In engineered cell lines containing αvβ3 receptors on the cell surface, Fn3 and GRGDSPAS ligands with specificity for the receptor can be internalized at both concentrations tested (70 nM and 7 μM). Polyvia-MPI is internalized only at higher concentrations due to different kinetics of the ligands. This demonstrates that rapid multivalent cellular internalization is achievable. [Figure 57] Figure 57 shows the incubation of a mAb with a binding polypeptide fused to a segment of Protein A (ZD). Salt is used to trigger phase separation of the binding polypeptide-mAb complex, which is then separated by centrifugation. The solution forms two phases: a protein-rich pellet containing the mAb-binding polypeptide complex in the precipitate, and a capture supernatant (SN). The pellet is resuspended in an elution buffer that dissociates the mAb from the binding polypeptide. The solution is centrifuged again, precipitating the binding polypeptide and separating it from the mAb, which remains suspended in the eluted SN. In this experiment, several mAb proteins (mAb1, 2, 3) were bound and eluted. DETAILED DESCRIPTION OF THE INVENTION

[0016] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. In case of conflict, the present specification, including definitions, will prevail. Preferred methods and materials are described below, but methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and are not intended to be limiting.

[0017] The terms "comprise," "include," "having," "has," "can," "contain," and variations thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not exclude the possibility of additional acts or structures. The singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments that "comprising," "consisting of," and "consisting essentially of" the embodiments or elements presented herein, whether explicitly stated or not.

[0018] For the specification of numerical ranges herein, each intermediate numerical value therebetween is expressly contemplated to the same degree of precision. For example, for the range of 6 to 9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range of 6.0 to 7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are expressly contemplated. As used herein, the term "about," when applied to one or more values ​​of interest, refers to a value similar to the stated reference value. In certain embodiments, unless otherwise stated or clear from the context, the term "about" refers to a range of values ​​that corresponds to 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater or less than) the stated reference value (except where such number would exceed 100% of possible values).

[0019] "Affinity" refers to the binding strength of a binding polypeptide for its target (ie, binding partner). An "agonist" refers to an entity that binds to a receptor and activates the receptor to produce a biological response. An "antagonist" blocks or inhibits the action or signaling of an agonist. An "inverse agonist" causes the opposite effect of an agonist. The activity of agonists, antagonists, and inverse agonists can be determined in vitro, in situ, in vivo, or a combination thereof. As used herein, "amino acid" refers to natural and unnatural synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to natural amino acids. Natural amino acids are those encoded by the genetic code. Amino acids may be referred to herein by either their commonly known three-letter symbols or the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Amino acids include side chains and polypeptide backbone moieties.

[0020] As used herein, the term "biomarker" refers to a naturally occurring biological molecule present in a subject at various concentrations that is useful for identifying and / or classifying a disease or condition. Biomarkers can include genes, proteins, polynucleotides, nucleic acids, ribonucleic acids, polypeptides, or other biological molecules used as indicators or markers of disease. In some embodiments, a biomarker comprises a disease marker. For example, a biomarker can be a gene that is upregulated or downregulated in subjects with a disease. As another example, a biomarker can be a polypeptide whose levels are increased or decreased in subjects with a disease or at risk of developing a disease. In some embodiments, a biomarker comprises a small molecule. In some embodiments, a biomarker comprises a polypeptide.

[0021] The terms "control," "reference level," and "reference" are used interchangeably herein. A reference level may be a predetermined value or range used as a benchmark for evaluating measurement results. A "control group," as used herein, refers to a group of control subjects. A predetermined level may be a cutoff value from a control group. A predetermined level may be an average from a control group. A cutoff value (or a predetermined cutoff value) may be determined by adaptive index model (AIM) methodology. A cutoff value (or a predetermined cutoff value) may be determined by receiver operating curve (ROC) analysis from biological samples of a patient group. ROC analysis, as commonly known in the biological field, is a determination of the test ability to determine the performance of each marker in distinguishing one condition from another, for example, in identifying patients with CRC. A description of ROC analysis is provided in PJ Heagerty et al. (Biometrics 2000, 56, 337-44), the disclosure of which is incorporated herein by reference in its entirety. Alternatively, a cutoff value may be determined by quartile analysis of biological samples from a patient group. For example, the cutoff value can be determined by selecting a value corresponding to any value in the range of the 25th to 75th percentile, preferably the value corresponding to the 25th, 50th or 75th percentile, more preferably the value corresponding to the 75th percentile. Such statistical analysis can be carried out using any method known in the art and can be implemented through any number of commercially available software packages (e.g., from Analyse-it Software Ltd., Leeds, UK; StataCorp LP, College Station, TX; SAS Institute Inc., Cary, NC). The healthy or normal level or range of target or protein activity can be defined according to standard practice.

[0022] The term "expression vector" refers to a plasmid, virus, or other vehicle known in the art into which a nucleic acid sequence for encoding a desired protein may be inserted or introduced. The term "host cell" refers to a cell that is susceptible to transformation, transfection, transduction, conjugation, etc., with a nucleic acid construct or expression vector. Host cells can be derived from plants, bacteria, yeast, fungi, insects, animals, etc. In some embodiments, host cells comprise Escherichia coli.

[0023] As used herein, "polymer" is intended to encompass homopolymers, heteropolymers, block polymers, copolymers, terpolymers, etc., as well as blends, combinations, and mixtures thereof. Polymers include, but are not limited to, functionalized polymers, such as polymers containing 5-vinyltetrazole monomer units and having a molecular weight distribution of less than 2.0. Polymers may be or include one or more of star block copolymers, linear polymers, branched polymers, hyperbranched polymers, dendritic polymers, comb polymers, graft polymers, brush polymers, bottle-brush copolymers, and crosslinked structures, such as block copolymers containing blocks of 5-vinyltetrazole monomer units. Polymers include, but are not limited to, polyesters, poly(meth)acrylamides, poly(meth)acrylates, polyethers, polystyrenes, polynorbornenes, and monomers with unsaturated bonds. For example, amphiphilic comb polymers are described in U.S. Patent Application Publication No. 2007 / 0087114 to Mayes et al. and U.S. Patent No. 6,207,749, the disclosures of each of which are incorporated herein by reference in their entireties. The amphiphilic comb polymer may exist in the form of a copolymer containing a backbone formed from a hydrophobic, water-insoluble polymer and side chains formed from short, hydrophilic, non-cell-binding polymers.Other polymers include, for example, polyalkylenes such as polyethylene and polypropylene; polychloroprene; polyvinyl ethers; polyvinyl ethers such as polyvinyl acetate; polyvinyl halides such as polyvinyl chloride; polysiloxanes; polystyrene; polyurethanes; poly(methyl (meth)acrylate), poly(ethyl (meth)acrylate), poly(n-butyl (meth)acrylate), poly(isobutyl (meth)acrylate), poly(tert-butyl (meth)acrylate), poly(hexyl (meth)acrylate), and poly(isodecyl (meth)acrylate). Examples of suitable polymers include polyacrylates such as poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate); polyacrylamides such as poly(acrylamide), poly(methacrylamide), poly(ethyl acrylamide), poly(ethyl methacrylamide), poly(N-isopropyl acrylamide), and poly(n-, iso-, and tert-butyl acrylamide); and copolymers and mixtures thereof. These polymers may also include useful derivatives, including polymers with substitutions; addition of chemical groups, e.g., alkyl groups, alkylene groups; hydroxylation; oxidation; and other modifications routinely performed by those skilled in the art. Polymers may also include zwitterionic polymers such as polyphosphorycholine, polycarboxybetaine, and polysulfobetaine. The polymer may have betaine, carboxybetaine, sulfobetaine, oligoethylene glycol (OEG), sarcosine, or polyethylene glycol (PEG) side chains. For example, poly(oligoethylene glycol methacrylate) (poly(OEGMA)) may be used. Poly(OEGMA) may be hydrophilic, water-soluble, non-staining, non-toxic, and non-immunogenic due to the OEG side chains.

[0024] As used herein, a "polynucleotide" may be single-stranded or double-stranded, or may contain portions of both double-stranded and single-stranded sequence. A polynucleotide may be a nucleic acid, natural or synthetic DNA, genomic DNA, cDNA, RNA, or a hybrid. A polynucleotide may contain a combination of deoxyribonucleotides and ribonucleotides, and a combination of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, and isoguanine. A polynucleotide may be obtained by chemical synthesis or recombinant methods.

[0025] A "peptide" or "polypeptide" is a linked sequence of two or more amino acids linked by peptide bonds. Polypeptides may be natural, synthetic, or modified or combined natural and synthetic forms. Peptides and polypeptides include proteins such as binding proteins, receptors, and antibodies. The terms "polypeptide," "protein," and "peptide" are used interchangeably herein. "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to the locally ordered three-dimensional structures within a polypeptide. These structures are commonly known as domains, such as enzymatic domains, extracellular domains, transmembrane domains, pore domains, and cytoplasmic tail domains. Domains are portions of polypeptides that form compact units of the polypeptide and are typically 15 to 350 amino acids in length. Exemplary domains include domains with enzymatic or ligand-binding activity. Typical domains are composed of small sections of organization, such as stretches of beta-sheets and alpha-helices. "Tertiary structure" refers to the complete three-dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three-dimensional structure formed by the noncovalent association of independent three-dimensional units.

[0026] The terms "reporter," "reporter group," "label," and "detectable label" are used interchangeably herein. A reporter can generate a detectable signal. A label can generate a signal detectable by visual or instrumental means. A variety of reporter groups can be used that differ in the physical nature of the signal transduction (e.g., fluorescence, electrochemistry, nuclear magnetic resonance (NMR), and electron paramagnetic resonance (EPR)) and the chemical nature of the reporter group. Various reporters include signal-generating substances such as chromagens, fluorescent compounds, chemiluminescent compounds, radioactive compounds, etc. In some embodiments, a reporter comprises a radioactive label. A reporter may comprise a light-generating moiety, such as an acridinium compound, and a fluorescence-generating moiety, such as fluorescein. In some embodiments, the signal from a reporter is a fluorescent signal. A reporter may comprise a fluorophore. Examples of fluorophores include, but are not limited to, acrylodan (6-acryloy1-2-dimethylaminonaphthalene), badane (6-bromo-acetyl-2-dimethylamino-naphthalene), rhodamine, naphthalene, dansylaziridine, 4-[N-[(2-iodoacetoxy)ethyl]-N-methylamino]-7-nitrobenz-2-oxa-1,3-diazole ester (IANBDE), 4-[N-[(2-iodoacetoxy)ethyl]-N-methylamino-7-nitrobenzo-2-oxa-1,3-diazole (IANBDA), fluorescein, dipyrrometheneboron difluoride (BODIPY), 4-nitrobenzo[c][1,2,5]oxadiazole (NBD), Alexa fluorochromes, and derivatives thereof. Fluorescein derivatives can include, for example, 5-fluorescein, 6-carboxyfluorescein, 3'6-carboxyfluorescein, 5(6)-carboxyfluorescein, 6-hexachlorofluorescein, 6-tetrachlorofluorescein, fluorescein, and isothiocyanate.

[0027] As used herein, "sample" or "test sample" can mean any sample in which the presence and / or level of a target is detected or determined. Samples can include liquids, solutions, emulsions, or suspensions. Samples may include medical samples. Samples may include any biological fluid or tissue such as blood, whole blood, blood fractions such as plasma and serum, muscle, interstitial fluid, sweat, saliva, urine, tears, synovial fluid, bone marrow, cerebrospinal fluid, nasal secretions, sputum, amniotic fluid, bronchoalveolar lavage fluid, gastric lavage fluid, vomit, feces, lung tissue, peripheral blood mononuclear cells, total white blood cells, lymph node cells, spleen cells, tonsil cells, cancer cells, tumor cells, bile, digestive fluids, skin, or combinations thereof. In some embodiments, the sample includes an aliquot. In other embodiments, the sample includes a biological fluid. Samples can be obtained by any means known in the art. Samples may be used directly as obtained from a patient or may be pre-treated to modify the properties of the sample by, for example, filtration, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, or any other method discussed herein or known in the art.

[0028] As used herein, the term "sensitivity" refers to the number of true positives divided by the number of true positives + the number of false negatives, and the sensitivity ("sens") can be in the range 0 < sens < 1. Ideally, embodiments of the methods herein have a number of false negatives equal to or close to zero so that a subject is not misidentified as not having a disease when the subject actually has the disease. Conversely, an assessment, a complementary measurement to sensitivity, of the ability of a prediction algorithm to correctly classify a negative is often performed. As used herein, the term "specificity" refers to the number of true negatives divided by the number of true negatives + the number of false positives, and the specificity ("spec") can be in the range 0 < spec < 1. Ideally, the methods described herein have a number of false positives equal to or close to zero, such that a subject is not misidentified as having a disease when the subject actually does not have the disease. Thus, a method with both sensitivity and specificity equal to 1, or 100%, is preferred. "Specifically binds" generally means that a polypeptide binds to a target more readily than it would to a random, unrelated target.

[0029] As used herein, "subject" may refer to a mammal that desires or requires the nanoparticles described herein containing one or more fusion proteins. The subject may be a human or a non-human animal. The subject may be a mammal. The mammal may be a primate or a non-primate. The mammal may be a primate, such as a human, or a non-primate, such as a dog, cat, horse, cow, pig, mouse, rat, camel, llama, goat, rabbit, sheep, hamster, or guinea pig, or a non-human primate, such as a monkey, chimpanzee, gorilla, orangutan, or gibbon. The subject may be of any age or developmental stage, such as an adult, adolescent, or infant.

[0030] "Transition" or "phase transition" refers to the aggregation of a thermoresponsive polypeptide. The phase transition occurs abruptly and reversibly at a specific temperature called the lower critical solution temperature (LCST) or inverse transition temperature (T^). Below the transition temperature, the thermoresponsive polypeptide (or a polypeptide containing a thermoresponsive polypeptide) is highly soluble. When heated above the transition temperature, the thermoresponsive polypeptide hydrophobically collapses and aggregates, forming a separate gel-like phase. "Inverse transition cycling" refers to a protein purification method for a thermoresponsive polypeptide (or a polypeptide containing a thermoresponsive polypeptide). The protein purification method may involve using the reversible phase transition behavior of the thermoresponsive polypeptide to cycle a solution through soluble and insoluble phases, thereby removing contaminants.

[0031] "Treatment" or "treating," when referring to the protection of a subject from a disease, means preventing, suppressing, repressing, ameliorating, or eliminating the disease. Preventing a disease involves administering a composition of the invention to a subject before the onset of the disease. Suppressing a disease involves administering a composition of the invention to a subject after the induction of the disease, before clinical manifestation. Suppressing or ameliorating a disease involves administering a composition of the invention to a subject after clinical manifestation of the disease.

[0032] "Substantially identical" can mean that the first and second amino acid sequences are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical over a region of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100 or more amino acids.

[0033] As used herein, "valency" refers to a potential binding unit or binding site. The term "multivalent" refers to a plurality of potential binding units. The terms "multimer" and "multivalent" are used interchangeably herein. "Variant," as used herein with respect to a polynucleotide, means (i) a portion or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or a portion thereof; (iii) a polynucleotide that is substantially identical to a referenced polynucleotide or its complement; or (iv) a polynucleotide that hybridizes under stringent conditions to a referenced polynucleotide, its complement, or a sequence substantially identical thereto.

[0034] A "variant" can be further defined as a peptide or polypeptide that differs in amino acid sequence by amino acid insertion, deletion, or conservative substitution but retains at least one biological activity. Representative examples of "biological activity" include the ability to be bound by a specific antibody or polypeptide or the ability to stimulate an immune response. A variant can refer to a substantially identical sequence. A variant can also refer to a functional fragment thereof. A variant can also refer to multiple copies of a polypeptide. The multiple copies may be in tandem or separated by a linker. A variant can also refer to a protein having an amino acid sequence that is substantially identical to a reference protein that retains at least one biological activity. Conservative amino acid substitutions, i.e., replacing an amino acid with an amino acid of different properties (e.g., hydrophilicity, degree and distribution of charged regions), are typically recognized as minor changes. These minor changes can be identified, in part, by considering the hydropathic index of the amino acid. See Kyte et al., J. Mol. Biol. 1982, 757, 105-132. The hydropathic index of an amino acid is based on consideration of its hydrophobicity and charge. It is known that amino acids with similar hydropathic indexes can be substituted and still retain protein function. In one embodiment, amino acids with hydropathic indexes of ±2 are substituted. The hydrophobicity of an amino acid can also be used to identify substitutions that result in a protein that retains biological function. Considering the hydrophilicity of amino acids in the context of a polypeptide allows for calculation of the maximum local average hydrophilicity of the polypeptide. Maximum local average hydrophilicity is a useful measure that has been reported to correlate well with antigenicity and immunogenicity, as discussed in U.S. Pat. No. 4,554,101, incorporated herein by reference. Substitution of amino acids with similar hydrophilicity values ​​can result in peptides that retain biological activity, such as immunogenicity, as is understood in the art. Substitutions can be made with amino acids with hydrophilicity values ​​within ±2 of each other.Both the hydrophobicity index and hydrophilicity value of an amino acid are influenced by the particular side chain of the amino acid. Consistent with that observation, it is understood that amino acid substitutions compatible with biological function depend on the relative similarity as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties of the amino acids, particularly the amino acid side chains.

[0035] A variant can be a polynucleotide sequence that is substantially identical over the entire length of the complete gene sequence or a fragment thereof. The polynucleotide sequence can be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the entire length of the gene sequence or a fragment thereof. A variant can be an amino acid sequence that is substantially identical over the entire length of the amino acid sequence or a fragment thereof. The amino acid sequence can be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the entire length of the amino acid sequence or a fragment thereof.

[0036] In recent years, advances in polymer synthesis technology have focused much research on the ability to probe specific biophysical properties of nanomaterials. Nearly every aspect of nanoparticle design is tested for its effectiveness in improving along some dimension (biocompatibility, pK, tissue migration, etc.). A brief list of parameters is highlighted in Figure 1, including a summary of optimal design specifications.

[0037] Size: Large particles (>1 μm) are internalized by macrophages, neutrophils, and dendritic cells. Particles smaller than 1 μm are internalized via pinocytosis or receptor-mediated endocytosis. Particles in the 40-50 nm range exhibit maximal uptake. Particles between 10 and 100 nm are the typical size range for optimizing biodistribution and clearance. Particles smaller than 5.5 nm are rapidly eliminated by the kidney. The curvature and conformation of the coronal chains appear to be particularly important in determining their fate in vivo. Shape: Rod-shaped designs are more easily taken up by cells than spherical ones. Non-spherical particles appear to have a longer circulation time than spherical particles. Surface chemistry: Charged nanoparticles have short blood circulation times and very nonspecific cellular uptake. This can be easily tailored with most synthetic polymer systems, but a neutral charge is generally optimal for most applications.

[0038] Corona hydrophobicity: Block copolymers with increased corona hydrophobicity are more likely to be taken up by cells but also exhibit higher levels of opsonization. For in vivo applications, optimal formulations vary, especially when targeted therapy is involved. Core stability: Micelle half-life can be controlled through core stability, as measured via pyrene I1 / I3 fluorescence. Other studies have shown that cross-linking the polymeric micelle core can also increase the half-life observed in vivo. Particle rigidity: Deformable structures cycle up to 30 times longer than rigid ones. Targeting / Stimulus-Responsive Elements: Targeting generally provides improved nanocarriers compared to nontargeted systems. However, the incorporation of targeting ligands or environmentally sensitive moieties often alters surface charge, morphology, or both. One study examined the effect of ligand density on tumor targeting and found that an optimal ratio exists for a particular cancer phenotype. This result indicates the existence of a trade-off between opsonization and targeting, which must be considered when introducing targeting ligands.

[0039] In synthetic polymer systems, the most challenging parameters to control are targeting / responsiveness and geometry. These design parameters often cannot be controlled in one-pot synthesis, necessitating multi-step construction. Multi-step processes almost inevitably introduce polydispersity / heterogeneity, which can obscure conclusions about specific design choices. In fact, recent studies have demonstrated that deviations of 10–20 nm can significantly affect nanoparticle behavior in the body. Therefore, despite all the advances in polymeric micelle synthesis, designing optimal micelle carriers remains challenging. In an ideal scenario, the optimal design elements for a specific application could be incorporated in advance during the design phase.

[0040] Morphology control of block copolymers: Microphase separation of diblock copolymers depends on three parameters: the volume fraction of both blocks combined, the total degree of polymerization, and the Flory-Huggins parameter (χ). The Chi parameter specifies the miscibility of both blocks, or immiscibility in the case of amphiphilic block copolymers. The Chi parameter is also a function of temperature. In a system consisting solely of block copolymers, the Chi parameter contains the interaction energy between the blocks AB, AA, and BB. Increasing the temperature or decreasing the Chi improves the compatibility between the blocks, increasing the combinatorial entropy and causing the copolymer to undergo an order-to-disorder transition.

[0041]

number

[0042] The main parameters of interest are the hydrophilicity of the corona-forming block, the hydrophilicity of the core block, the total length of the copolypeptide, and the ratio of the two blocks. The parameters evaluated are size, morphology, stability, and thermoresponsive behavior. All measurements were performed in 140 mM NaCl, 10 mM phosphate buffer, 3 mM KCl, pH 7.4 unless otherwise noted. Size was measured by dynamic light scattering (DLS) and static light scattering (SLS), respectively, and the hydrodynamic radius (R h ) and radius of gyration (R g ) was evaluated by R g and R h Combining these, we obtain the shape factor ρ=R, which gives a rough indication of the shape of the scatterer. g / R hA shape factor of 1.505 suggests Gaussian polymer chains, 1.0 suggests hollow spheres or vesicles, and 0.775 suggests solid spheres. For elongated scatterers, the shape factor depends on the aspect ratio. A combination of temperature-dependent turbidity and DLS was used to determine the phase behavior of block copolypeptides. Cryogenic transmission electron microscopy (cryo-TEM) was used to evaluate the morphology and provide important insights into the hydration of core / corona chains. The stability of the assembled nanostructures was determined by the shift in the pyrene I1 / I3 fluorescence bands, as previously described.

[0043] One of the target domains selected for the second part of this study is the tenth type III domain from human fibronectin (Fn3), which targets human αvβ3 integrin. This receptor is upregulated on the endothelium of many tumors and is also overexpressed in some tumor cells, such as glioblastoma, renal cell carcinoma, ovarian cancer, and breast cancer metastases. It has a low affinity (K) for αvβ3 integrin. D >1×10 -7 We previously showed that Fn3 domains can be expressed in E. coli as fusions to repeat polypeptides such as ELP, selecting Fn3 variants that bind at the ATP-binding site (M). Multivalent presentation allows for amplification of avidity that would likely not be possible with intrinsically high-affinity ligands, and the low affinity of the parent Fn3 domain is important because it allows us to test the effects of self-assembly and multivalency on binding avidity and cellular uptake.

[0044] fusion proteins The term "fusion protein" as used herein comprises at least one unstructured polypeptide and at least one binding polypeptide. A fusion protein may optionally comprise at least one linker.

[0045] In some embodiments, a fusion protein comprises two or more unstructured polypeptides. The fusion protein may comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 unstructured polypeptides. The fusion protein may comprise fewer than 30, fewer than 25, or fewer than 20 unstructured polypeptides. The fusion protein may comprise 1 to 30, 1 to 20, or 1 to 10 unstructured polypeptides. In such embodiments, the unstructured polypeptides may be identical to or different from one another. In some embodiments, the fusion protein comprises two or more unstructured polypeptides arranged in tandem with one another. In one embodiment, the fusion protein comprises a diblock of two unstructured polypeptides with various repeats of the two individual unstructured polypeptides.

[0046] In some embodiments, a fusion protein comprises two or more binding polypeptides. The fusion protein may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 binding polypeptides. The fusion protein may comprise fewer than 30, fewer than 25, fewer than 20, fewer than 10, or fewer than five binding polypeptides. The fusion protein may comprise 1 to 30, 1 to 20, or 1 to 10 binding polypeptides. In such embodiments, the binding polypeptides may be identical to or different from one another. In some embodiments, the fusion protein comprises two or more binding polypeptides arranged in tandem with one another. In some embodiments, the fusion protein comprises two to six binding polypeptides. In some embodiments, the fusion protein comprises two binding polypeptides. In some embodiments, the fusion protein comprises three binding polypeptides. In some embodiments, the fusion protein comprises four binding polypeptides. In some embodiments, the fusion protein comprises five binding polypeptides. In some embodiments, the fusion protein comprises six binding polypeptides.

[0047] In some embodiments, the fusion protein may be arranged as a modular linear polypeptide. For example, the modular linear polypeptide may be arranged in one of the following structures: [UPX] n -[UPY] m -[BP] p ; [UPY] m -[UPX] n -[BP] p ; [BP] p -[UPX] n -[UPY] m ; [BP] p -[UPY]m -UPX] n ; [UPX] n -[BP] p -[UPY] m ; [UPY] m -[BP] p -[UPX] n ; [BP] p -[UPX] n -[UPY] m -[BP] p ; [BP] p -[UPY] m -[UPX] n -[BP] p ; [BP] p -[UPX] n -[BP] p -[UPY] m -[BP] p ; [BP] p -[UPY} m -[BP] p -[UPX] n -[BP] p ; wherein UPX refers to unstructured protein X, UPY refers to unstructured protein Y, and BP refers to a binding polypeptide, wherein unstructured polypeptide X is an unstructured polypeptide different from unstructured polypeptide Y; n, m, and p are each independently an integer greater than or equal to 1; and "-" represents a bond or a linker moiety. In some embodiments, n is an integer between 20 and 200. In one aspect, n is between 40 and 200. In some embodiments, m is an integer between 20 and 200. In one aspect, n is between 40 and 200. In some embodiments, p is an integer less than or equal to 10. In some embodiments, p is an integer equal to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, at least one binding polypeptide is positioned N-terminal to at least one unstructured polypeptide. In some embodiments, at least one binding polypeptide is positioned C-terminal to at least one unstructured polypeptide. Other repeats of the motif shown are contemplated and are within the scope of this disclosure.

[0048] The fusion protein can be recombinantly expressed in a host cell by a person skilled in the art. The fusion protein can be purified by any means known to a person skilled in the art. For example, the fusion protein can be purified using chromatography, such as liquid chromatography, size exclusion chromatography, or affinity chromatography, or a combination thereof. In some embodiments, the fusion protein is purified without chromatography. In some embodiments, the fusion protein is purified using a reverse transition cycle. In one embodiment, the fusion protein comprises a core polypeptide linked to a binding polypeptide. n -corona m It comprises a diblock, where n is the number of repeats between 20 and 200, and m is the number of repeats between 40 and 200. In one embodiment, the binding polypeptide comprises Fn3, Tn3, the alpha helix Z domain of Staphylococcus aureus protein A, one or more targeting peptides, anti-EGFR binding proteins, DARPINS, knottins, or scFv. In one embodiment, the fusion protein comprises an RLP linked to a binding polypeptide. n -ELP m It comprises a diblock, where n is the number of repeats between 20 and 200, and m is the number of repeats between 40 and 200. In one embodiment, the binding polypeptide comprises Fn3, Tn3, an alpha helix Z domain of Staphylococcus aureus protein A, one or more targeting peptides, an anti-EGFR binding protein, DARPINS, a knottin, or an scFv.

[0049] Unstructured Polypeptides An unstructured polypeptide may include any polypeptide that has minimal or no secondary structure as observed by CD, is soluble below its lower critical solution temperature (LCST) and / or above its upper critical solution temperature (UCST), and contains a repetitive amino acid sequence. The LCST is the temperature below which a polypeptide is miscible. The UCST is the temperature above which a polypeptide is miscible. In some embodiments, an unstructured polypeptide has only UCST behavior. In some embodiments, an unstructured polypeptide has only LCST behavior. In some embodiments, an unstructured polypeptide has both UCST and LCST behavior. An unstructured polypeptide may contain a repetitive amino acid sequence. An unstructured polypeptide may have an LCST of about 0°C to about 100°C, about 10°C to about 50°C, or about 20°C to about 42°C. The unstructured polypeptide may have a UCST of about 0°C to about 100°C, about 10°C to about 50°C, or about 20°C to about 42°C. In some embodiments, the unstructured polypeptide has a transition temperature between room temperature (about 25°C) and body temperature (about 37°C). In some embodiments, the fusion protein comprising one or more thermoresponsive polypeptides has a transition temperature between room temperature (about 25°C) and body temperature (about 37°C). In some embodiments, the unstructured polypeptide does not have LCST or UCST behavior. The unstructured polypeptide may have an LCST or UCST below or above body temperature at the concentrations at which nanoparticles comprising one or more fusion proteins are administered to a subject.

[0050] In some embodiments, the unstructured polypeptide comprises one or more thermoresponsive polypeptides, which may include, for example, elastin-like polypeptides (ELPs) and resilin-like proteins (RLPs). In some embodiments, the unstructured polypeptide comprises a plurality of unstructured polypeptides. In one aspect, the unstructured polypeptide comprises a diblock of two or more unstructured polypeptides. In one aspect, the unstructured polypeptide comprises a diblock of a resilin-like protein (RLP) and an elastin-like polypeptide (ELP).

[0051] In one embodiment, the unstructured polypeptide comprises one or more core polypeptides. In one aspect, the core polypeptide is a resilin-like polypeptide (RLP). RLPs are derived from arthropod Recl-resilin. Recl-resilin is environmentally responsive and exhibits dual phase transition behavior. Thermoresponsive RLPs can have LCSTs and UCSTs (Li et al., Macromol. Rapid Commun. 2015, 36, 90-95). Further examples of suitable thermoresponsive polypeptides are described in U.S. Patent Application Publication Nos. 2012 / 0121709 and 2015 / 0112022, each of which is incorporated herein by reference. In one embodiment, the RLP polypeptide comprises the sequence QYPSDGRG (SEQ ID NO: 1). The unstructured polypeptide is (QYPSDGRG) nwhere n is 20 to 200. In some embodiments, n is 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300. In some embodiments, n may be less than 500, less than 400, less than 300, less than 200, or less than 100. In some embodiments, n may be 1 to 500, 1 to 400, 1 to 300, or 1 to 200. In some embodiments, n is 20, 40, 60, 80, 100, 120, 160, 180, or 200. In one aspect, n is the number of repeats of the RLP, between 20 and 200. The RLP may be recombinantly expressed.

[0052] In another embodiment, the unstructured polypeptide comprises one or more corona polypeptides. In one aspect, the corona polypeptide comprises an elastin-like polypeptide (ELP). Elastin-like polypeptide (ELP) refers to a polypeptide comprising the sequence VPG[A:G]G (SEQ ID NO: 8). The unstructured polypeptide is (VPG[A:G]G) n (wherein n is 40 to 200). In some embodiments, n is 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300. In some embodiments, n may be less than 500, less than 400, less than 300, less than 200, or less than 100. In some embodiments, n may be 1 to 500, 40 to 400, 1 to 300, or 40 to 200. In some embodiments, n is 20, 40, 60, 80, 100, 120, 160, 180, or 200. In one embodiment, n is the number of repeats of the ELP, between 40 and 200. The ELP may be recombinantly expressed.

[0053] The unstructured polypeptide may further comprise additional amino acids at the C- or N-terminus of the ELP or RLP motif. These amino acids surrounding the motif may be part of an overall repeated motif. The amino acids surrounding the motif may balance the overall hydrophobicity and / or charge to control the LCST or UCST behavior of the unstructured polypeptide. In one embodiment, the unstructured polypeptide is an RLP. n -ELP m wherein n is the number of repeats from 20 to 200 and m is the number of repeats from 40 to 200. In one embodiment, the unstructured polypeptide comprises an RLP 40 -ELP 40 (SEQ ID NO: 83), RLP 40 -ELP 80 (SEQ ID NO: 84), RLP 80 -ELP 80 (SEQ ID NO: 87), or RLP 80 -ELP 160 (SEQ ID NO: 86).

[0054] Thermoresponsive polypeptides, such as ELPs and RLPs, can have a phase transition. Thermoresponsive polypeptides can impart phase transition properties to unstructured polypeptides or fusion proteins. A "phase transition" or "transition" can refer to a lower critical solution temperature (LCST) or inverse transition temperature (T t The term "thermoresponsive polypeptide aggregation" can refer to the rapid and reversible aggregation of a thermoresponsive polypeptide that occurs at a specific temperature called the transition temperature (LCST or T t ), the thermoresponsive polypeptide (or a polypeptide comprising the thermoresponsive polypeptide) may be highly soluble. When heated above the transition temperature, the thermoresponsive polypeptide may hydrophobically collapse and aggregate to form a separate gel-like phase.

[0055] The thermoresponsive polypeptide may undergo a phase transition at various temperatures and concentrations. The thermoresponsive polypeptide, such as ELP, may not have any effect on the binding or efficacy of the binding polypeptide. The thermoresponsive polypeptide may allow the user to adjust the transition temperature, molecular weight, and format of the fusion protein as desired. Thermoresponsive polypeptides may exhibit inverse phase transition behavior, and thus fusion proteins containing thermoresponsive polypeptides may exhibit inverse phase transition behavior. For controlled release (sustained release) of the fusion protein, the inverse phase transition behavior may be used to form a drug depot within the target tissue. The inverse phase transition behavior may also enable the purification of the fusion protein using an inverse phase transition cycle, thereby eliminating the need for chromatography.

[0056] Binding Polypeptides A binding polypeptide (or "targeting polypeptide") may include any polypeptide capable of binding to at least one target. A binding polypeptide may bind to at least one target. A "target" may be an entity capable of being bound by a binding polypeptide. A target may include, for example, another polypeptide, a cell surface receptor, a carbohydrate, an antibody, a small molecule, or a combination thereof. A target may be a biomarker. A target may be activated via agonism or blocked via antagonism. A binding polypeptide may specifically bind to a target. By binding to a target, a binding polypeptide may act as a targeting moiety, an agonist, an antagonist, or a combination thereof. In some embodiments, the binding polypeptide domain binds to TRAILR-2. "TRAIL receptor 2" or "TRAILR-2" refers to the TNF-related apoptosis-inducing ligand (TRAIL) receptor 2 protein. TRAILR-2 activates apoptosis or programmed cell death in tumor cells upon binding to TRAIL or other agonists. In some embodiments, the binding polypeptide domain binds to epidermal growth factor receptor (EGFR). Upon binding of epidermal growth factor (EGF) and other growth factor ligands, EGFR activates signaling pathways that promote cell proliferation.

[0057] The binding polypeptide may be a monomer that binds to a target. The monomer may bind to one or more targets. The binding polypeptide may form an oligomer. The binding polypeptide may form an oligomer with the same or different binding polypeptides. The oligomer may bind to a target. The oligomer may bind to one or more targets. One or more monomers in an oligomer may bind to one or more targets. In some embodiments, the fusion protein is multivalent. In some embodiments, the fusion protein binds to multiple targets. In some embodiments, the activity of the binding polypeptide alone is the same as the activity of the binding protein when it is part of a fusion protein. In some embodiments, the binding polypeptide comprises one or more scaffold proteins. As used herein, "scaffold protein" refers to one or more polypeptide domains that are relatively stable and have a defined three-dimensional structure. The scaffold protein may further have the capacity for affinity engineering. In some embodiments, the scaffold protein is engineered to bind to a specific target. The scaffold proteins may be the same or different.

[0058] In some embodiments, the scaffold protein comprises a fibronectin domain. Fibronectin is a high-molecular-weight glycoprotein of the extracellular matrix that binds to membrane-spanning receptor proteins called integrins. Fibronectin binds to extracellular matrix components such as collagen, fibrin, and heparan sulfate proteoglycans. Human fibronectin exists as a protein dimer, containing two nearly identical polypeptide chains linked by a pair of C-terminal disulfide bonds. Each human fibronectin subunit contains three domains: type I, type II, and type III. Fibronectin type III (Fn3) refers to the third of three internal repeats in human fibronectin. This domain is often referred to as a scaffold protein because it contains three CDR-like (complementarity-determining region) loops that can be engineered to bind to a protein of interest using molecular biology techniques. In some embodiments, the fibronectin domain comprises Tn3. "Tn3" or "Tn3 scaffold" refers to the Fn3 domain derived from human tenascin-C. Tn3 may comprise the amino acid sequence of SEQ ID NO: 62. In some embodiments, Tn3 binds to TRAIL receptor 2 (SEQ ID NO: 68). In one embodiment, the binding protein comprises a type III domain from human fibronectin (Fn3) (SEQ ID NO: 60). In another embodiment, the binding protein comprises Tn3 (SEQ ID NO: 62). In another embodiment, the binding protein comprises the alpha helix Z domain of Staphylococcus aureus protein A (SEQ ID NO: 64). In other embodiments, the binding polypeptide may comprise one or more proteins selected from, for example, an anti-EGFR binding protein, a DARPINS, a knottin, or an scFv.

[0059] In some embodiments, the binding polypeptide comprises an amino acid sequence comprising Arg-Gly-Asp-Ser (RGDS). In another embodiment, the binding polypeptide comprises the amino acid sequence Gly-Arg-Gly-Asp-Ser-Pro-Ala-Ser (GRGDSPAS; SEQ ID NO: 76). In some embodiments, the binding polypeptide comprises a plurality of amino acid sequences consisting of SEQ ID NOs: 60-64, 74-78. The amino acid sequences of SEQ ID NOs: 60-64, 74-78 can be present anywhere within the binding polypeptide. In some embodiments, the amino acid sequences of SEQ ID NOs: 60-64, 74-78 can be repeated consecutively within the binding polypeptide.

[0060] Other examples of binding proteins include one or more of an ErbB2 receptor binding protein (ANHP) having the sequence of SEQ ID NO:74, a cell binding peptide (GRGDSPAS) having the sequence of SEQ ID NO:76, an adenovirus (AAV) binding protein (PKD2) having the sequence of SEQ ID NO:112, an adenovirus (AdV) binding protein (CAR) having the sequence of SEQ ID NO:114, a lentivirus (LV) binding protein CR2 having the sequence of SEQ ID NO:116, a lentivirus (LV) binding protein CR3 having the sequence of SEQ ID NO:118, or an albumin binding protein (ABP) having the sequence of SEQ ID NO:120.

[0061] Linker In some embodiments, the fusion protein further comprises at least one linker. In some embodiments, the fusion protein comprises two or more linkers. In such embodiments, the linkers may be the same or different from one another. The fusion protein may comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, or at least 100 linkers. The fusion protein may contain fewer than 500, fewer than 400, fewer than 300, or fewer than 200 linkers. The fusion protein may contain 1 to 1000, 10 to 900, 10 to 800, or 5 to 500 linkers.

[0062] The linker may be positioned between the binding polypeptide and the unstructured polypeptide, between the binding polypeptides, between the unstructured polypeptides, or a combination thereof. Multiple linkers may be positioned adjacent to each other. Multiple linkers may be positioned adjacent to each other between the binding polypeptide and the unstructured polypeptide.

[0063] The linker can be a polypeptide of any amino acid sequence and length. The linker may act as a spacer peptide. The linker may be between polypeptide domains. The linker may sufficiently separate the binding domains of the binding polypeptides while retaining the activity of the binding domains. In some embodiments, the linker comprises a charged amino acid. In some embodiments, the linker is flexible. In some embodiments, the linker comprises at least one glycine and at least one serine. In some embodiments, the linker comprises an amino acid sequence consisting of (Gly4Ser)3 (SEQ ID NO: 66). In some embodiments, the linker comprises at least one proline.

[0064] Polynucleotides Further provided are polynucleotides encoding the fusion proteins described herein. A vector may contain the polynucleotide encoding the fusion protein described herein. To obtain polypeptide expression, the polynucleotide encoding the polypeptide is typically subcloned into an expression vector containing a promoter to direct transcription, a transcription / translation terminator, and, in the case of a nucleic acid encoding a protein, a ribosome binding site for translation initiation. An exemplary vector is pET24 (SEQ ID NO: 121). Suitable bacterial promoters are well known in the art. Also provided are host cells transformed or transfected with an expression vector containing a polynucleotide encoding the fusion protein described herein. Bacterial expression systems for protein expression are available, for example, in Escherichia coli, Bacillus sp., and Salmonella (Paiva et al., Gene 1983, 22, 229-235; Mosbach et al. Nature 1983, 302, 543-545). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and commercially available. Retroviral expression systems can be used in the present invention. In some embodiments, the fusion protein comprises one or more repeats or a single sequence of SEQ ID NO: 18, 20, 22, 24, 26, 28, 30, 34, 36, 38, 40, 42, 44, 46, 48, 50, 60, 62, 64, 74, 76, or 78. In some embodiments, the fusion protein comprises one or more repeats or a single sequence of a polypeptide encoded by any one of the polynucleotide sequences of SEQ ID NO: 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, or 79. In some embodiments, the fusion protein comprises a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 80-110.

[0065] nanoparticles Nanoparticles comprising one or more of the fusion proteins described herein can be produced by self-assembly of the fusion proteins. As described herein, the identity and number of repeats of the diblock affect nanoparticle formation.

[0066] Crosslinking agent In one embodiment, the nanoparticles are crosslinked to improve their stability and half-life in biological media. Crosslinking can be achieved by chemical methods targeting primary amine, carboxyl, sulfhydryl, or carbonyl moieties. Exemplary crosslinking agents include carbodiimides (e.g., EDC), NHS esters, imidoesters (pentafluorophenyl esters, hydroxymethylphosphine), maleimides, haloacetyls (e.g., bromoacetyl or iodoacetyl), pyridyl disulfides, thiosulfonates, vinyl sulfones, hydrazines, alkoxyamines, diazirines, aryl azides, isocyanates, formaldehyde, glutaraldehyde, and the like. In other embodiments, crosslinking can be achieved by incorporating crosslinkable natural amino acids (e.g., cysteine ​​to form cystine), or modified amino acids, or chemically reactive amino acids that can be activated to form crosslinks.

[0067] The typical crosslinker used herein is p-azido-L-phenylalanine (pAzF). Crosslinking can be achieved by photoactivation of the N3 bond, which can insert at any peptide bond or generate decomposable free radicals in the presence of another radical N3 group. Solutions are prepared by resuspending the peptide from a lyophilized powder to a working concentration, typically greater than 50 nM, and exposing it to high-intensity UV light for 0.1–30 seconds. Chemical crosslinking can also be used; a chemical linker is added after lyophilization or resuspension with the diblock peptide.

[0068] Administration Nanoparticles containing one or more fusion proteins described herein can be formulated according to standard techniques known to those skilled in the art to form therapeutic or targeted delivery agents. Such compositions containing nanoparticles containing one or more fusion proteins can be administered at dosages and with techniques known to those skilled in the art, taking into account factors such as the age, sex, weight, and condition of the particular subject, as well as the route of administration. Nanoparticles containing one or more fusion proteins can be administered prophylactically or therapeutically. In prophylactic administration, nanoparticles can be administered in an amount sufficient to induce a response. In therapeutic applications, nanoparticles are administered to a subject in need thereof in an amount sufficient to induce a therapeutic effect. The amount adequate to achieve this is defined as a "therapeutically effective amount." The amount effective for this use depends, for example, on the specific composition of the nanoparticle regimen administered, the method of administration, the stage and severity of the disease, the patient's general health, and the judgment of the prescribing physician. Nanoparticles can be administered by methods well known in the art, such as those described in Donnelly et al., Ann. Rev. Immunol. 1997, 75, 617-648; U.S. Patent No. 5,580,859 to Feigner et al., U.S. Patent No. 5,703,055 to Feigner, and U.S. Patent No. 5,679,647 to Carson et al., the contents of each of which are incorporated herein by reference in their entirety. Nanoparticles can also be conjugated to particles or beads that can be administered to individuals using, for example, a vaccine gun. Those skilled in the art will know that the selection of a pharmaceutically acceptable carrier, including a physiologically acceptable compound, depends, for example, on the route of administration.

[0069] Nanoparticles can be delivered via various routes. Typical delivery routes include parenteral administration, such as intradermal, intramuscular, or subcutaneous delivery. Other routes include oral administration, intranasal, intravaginal, transdermal, intravenous, intraarterial, intratumoral, intraperitoneal, and epidermal routes. In some embodiments, nanoparticles are administered to a subject intravenously, intraarterially, or intraperitoneally.

[0070] The nanoparticles may be in a liquid preparation such as a suspension, syrup, or elixir. The nanoparticles may be incorporated into liposomes, microspheres, or other polymer matrices (see, e.g., U.S. Pat. No. 5,703,055 to Feigner et al., the contents of which are incorporated herein by reference in their entirety; Gregoriadis, Liposome Technology, Vols. I to III (2002)). nd Liposomes can be composed of phospholipids or other lipids and can be non-toxic, physiologically acceptable, and metabolizable carriers that are relatively simple to prepare and administer.

[0071] Nanoparticles can be used as vaccines.Vaccines can be administered by electroporation, such as the method described in U.S. Patent No. 7,664,545, which is incorporated herein by reference.Electroporation can be carried out by the method or device described in U.S. Patent Nos. 6,302,874, 5,676,646, 6,241,701, 6,233,482, 6,216,034, 6,208,893, 6,192,270, 6,181,964, 6,150,148, 6,120,493, 6,096,020, 6,068,650 and 5,702,359, the contents of each of which are incorporated herein by reference in their entirety. Electroporation can be performed via a minimally invasive device.

[0072] In some embodiments, the nanoparticles are administered in a controlled-release formulation. In some embodiments, the nanoparticles comprise one or more thermoresponsive polypeptides, which have a transition temperature such that the nanoparticles remain soluble before administration and undergo a transition upon administration to a gel-like depot in a subject. In some embodiments, the nanoparticles comprise one or more fusion proteins comprising one or more thermoresponsive polypeptides, which have a transition temperature such that the fusion protein remains soluble at room temperature and undergoes a transition upon administration to a gel-like depot in a subject. For example, in some embodiments, the fusion protein comprises one or more thermoresponsive polypeptides, which have a transition temperature between room temperature (about 25°C) and body temperature (about 37°C) at which the fusion protein can be administered to form a depot. As used herein, "depot" refers to a gel-like composition comprising a fusion protein that releases the fusion protein over time. In some embodiments, the nanoparticles can be injected subcutaneously or intratumorally to form a depot (coacervate). The depot can provide controlled (sustained) release of the nanoparticles. The depot can provide, for example, sustained release of nanoparticles into the circulation or tumor. In some embodiments, the nanoparticles can be released from the depot over a period of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 1 week, at least about 1.5 weeks, at least about 2 weeks, at least about 2.5 weeks, at least about 3.5 weeks, at least about 4 weeks, or at least about 1 month.

[0073] detection As used herein, the terms "detect" or "determine the presence" refer to a qualitative measurement of undetectable, low, normal, or high concentrations of one or more nanoparticles, targets, or nanoparticles bound to a target. Detection may include in vitro, ex vivo, or in vivo detection. Detection may include detecting the presence of one or more nanoparticles containing one or more nanoparticles or targets relative to the absence of one or more nanoparticles or targets. Detection may also include quantification of the level of one or more nanoparticles or targets. The terms "quantify" or "quantification" may be used interchangeably and may refer to the process of determining the amount or abundance of a substance (e.g., nanoparticle or target), whether relative or absolute. Any suitable detection method is within the general scope of this disclosure. In some embodiments, the nanoparticles include a reporter attached thereto for detection. In some embodiments, the nanoparticles are labeled with a reporter. In some embodiments, detection of target-bound nanoparticles may be determined by methods including, but not limited to, band intensity on a Western blot, flow cytometry, radiolabeled imaging, cell binding assays, activity assays, SPR, immunoassays, or a variety of other methods known in the art.

[0074] In some embodiments, any immunoassay may be utilized, provided that the nanoparticles contain antibody mimics for binding and / or detecting the target. The immunoassay may be an enzyme-linked immunoassay (ELISA), a radioimmunoassay (RIA), a competitive inhibition assay (e.g., forward or reverse competitive inhibition assay), a fluorescence polarization assay, or a competitive binding assay. The ELISA may be a sandwich ELISA. Specific immunological binding of the nanoparticles to the target can be detected via a direct label attached to the nanoparticles or via an indirect label, such as alkaline phosphatase or horseradish peroxidase. The use of immobilized nanoparticles can be incorporated into immunoassays. The nanoparticles can be immobilized on a variety of supports, such as magnetic or chromatographic matrix particles, the surface of an assay plate (e.g., microtiter well), or a piece of solid substrate material. An assay strip can be prepared by coating a nanoparticle or nanoparticles in an array on a solid support. The strip can then be immersed in a test biological sample and rapidly processed through washing and detection steps to generate a measurable signal, such as a colored spot.

[0075] Methods of Treating Disease The present invention is directed to a method for treating a disease in a subject in need thereof. The method may comprise administering to the subject an effective amount of nanoparticles comprising one or more nanoparticles described herein. The disease may be selected from cancer, metabolic disease, autoimmune disease, cardiovascular disease, and orthopedic disorder. In some embodiments, the disease is a disease associated with the target of at least one binding polypeptide. Metabolic disease can occur when abnormal chemical reactions in the body change normal metabolic process.Metabolic disease can include, for example, insulin resistance, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance disease, cardiovascular disease, arteriosclerosis, lipid-related metabolic disorder, hyperglycemia, hyperinsulinemia, hyperlipidemia and glucose metabolism disorder.

[0076] Autoimmune diseases result from the body's abnormal immune response to substances and tissues that are normally present in the body.Autoimmune diseases include, but are not limited to, lupus, rheumatoid arthritis, multiple sclerosis, insulin-dependent diabetes mellitus, myasthenia gravis, Graves' disease, autoimmune hemolytic anemia, autoimmune thrombocytopenia, purpura, Goodpasture's syndrome, pemphigus vulgaris, acute rheumatic fever, post-streptococcal glomerulonephritis, polyarteritis nodosa, myocarditis, psoriasis, celiac disease, Crohn's disease, ulcerative colitis and fibromyalgia. Cardiovascular disease is a type of disease that involves the heart or blood vessels.Cardiovascular disease can include, for example, coronary artery disease (CAD), such as angina pectoris and myocardial infarction (heart attack), stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, cardiac arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysm, peripheral arterial disease and venous thrombosis. Orthopedic or musculoskeletal disorders are injuries or pain to the body's joints, ligaments, muscles, nerves, tendons, and structures that support the limbs, neck, and back. Orthopedic disorders may include degenerative diseases and inflammatory conditions that cause pain and impair normal activity. Orthopedic disorders may include, for example, carpal tunnel syndrome, epicondylitis, and tendonitis. Cancer may include, but is not limited to, breast cancer, colorectal cancer, colon cancer, lung cancer, prostate cancer, testicular cancer, brain cancer, skin cancer, rectal cancer, stomach cancer, esophageal cancer, sarcoma, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, ovarian cancer, lymphatic system cancer, cervical cancer, vulvar cancer, melanoma, mesothelioma, kidney cancer, bladder cancer, thyroid cancer, bone cancer, carcinoma, sarcoma, and soft tissue cancer. In some embodiments, the cancer is colorectal cancer. In some embodiments, the cancer is colorectal adenocarcinoma.

[0077] One application of protein therapeutics is the treatment of cancer. In certain embodiments, the present invention provides a method for using scaffold proteins in the development of antibody mimics for targeted tumor targets. The advent of scaffold protein engineering has created the possibility of designing potent protein drugs that are not hindered by steric and architectural constraints. Potent protein drugs can be valuable for diagnosis or treatment, but successful delivery to the target area can present a significant challenge.

[0078] How to diagnose a disease Provided herein are methods for diagnosing disease. The method may include administering nanoparticles comprising one or more fusion proteins described herein to a subject and detecting binding of the nanoparticles to a target to determine the presence of the target in the subject. The presence of the target may indicate disease in the subject. In other embodiments, the method may include contacting a sample from the subject with the nanoparticles described herein, determining the level of the target in the sample, and comparing the level of the target in the sample with a control level of the target, wherein a level of the target that differs from the control level indicates disease in the subject. In some embodiments, the disease is selected from cancer, metabolic disease, autoimmune disease, cardiovascular disease, and orthopedic disorder, as detailed above. In some embodiments, the target comprises a disease marker or biomarker. In some embodiments, the nanoparticles may function as antibody mimics to bind to or detect the target.

[0079] Methods for determining the presence of a target Provided herein is a method for determining the presence of a target in a sample.The method may include contacting a sample with nanoparticles comprising one or more fusion proteins described herein under conditions that allow the formation of a complex between the nanoparticles and the target in the sample, and detecting the presence of the complex.The presence of the complex can indicate the presence of the target in the sample.In some embodiments, the nanoparticles are labeled with a reporter for detection. In some embodiments, the sample is obtained from a subject and the method further comprises diagnosing, prognosing, or evaluating the effectiveness of a treatment for the subject. When the method comprises evaluating the effectiveness of a treatment for the subject, the method may further comprise modifying the treatment for the subject as necessary to improve effectiveness.

[0080] Methods for determining the effectiveness of a treatment Provided herein is a method for determining the effectiveness of a treatment for a disease in a subject who needs to determine the effectiveness of the treatment for the disease.The method can include: contacting a sample from the subject with nanoparticles comprising the fusion protein described herein under conditions that allow the nanoparticles in the sample to form complexes with a target; determining the level of the complex in the sample, which indicates the level of the target in the sample; and comparing the level of the target in the sample with the control level of the target; if the level of the target is different from the control level, the treatment is determined to be effective or ineffective in treating the disease.

[0081] The time points may include various time points before the onset of disease, before administration of treatment, during administration of treatment, and after treatment has ended, or a combination thereof. When nanoparticles containing one or more fusion proteins are administered to a subject, the nanoparticles can bind to a target, wherein the presence of the target indicates the presence of disease in the subject at various time points. In some embodiments, the target comprises a disease marker or biomarker. In some embodiments, the nanoparticles can act as antibody mimics to bind to and / or detect the target. Comparing the binding of the nanoparticles to the target at various time points can indicate whether the disease is progressing, whether the disease has developed, whether the treatment is working to treat or prevent the disease, or a combination thereof.

[0082] In some embodiments, the control level corresponds to a level in the subject at a time point before or during the period when the subject begins treatment, and the sample is taken from the subject at a later time point. In some embodiments, the sample is taken from the subject at a time point when the subject is receiving treatment, and the control level corresponds to a disease-free level or a level at a time point before the period when the subject begins treatment. In some embodiments, the method further includes changing the treatment or administering a different treatment to the subject when it is determined that the treatment is not effective in treating the disease.

[0083] It will be apparent to those skilled in the art that suitable modifications and adaptations to the compositions, formulations, methods, processes, and applications described herein may be made without departing from the scope of any embodiment or aspect thereof. The compositions and methods provided are exemplary and are not intended to limit the scope of any particular embodiment. All of the various embodiments, aspects, and options described herein can be combined in any variation or iteration. The scope of the compositions, formulations, methods, and processes described herein includes all actual or potential combinations of the embodiments, aspects, options, examples, and preferences described herein. The exemplary compositions and formulations described herein may omit any component disclosed herein, substitute any component, or include any component disclosed elsewhere herein. In the unlikely event that the meaning of a term in any patent or publication incorporated by reference conflicts with the meaning of the term as used in this disclosure, the meaning of the term or phrase in this disclosure shall control. Furthermore, the foregoing description merely discloses and describes exemplary embodiments. All patents and publications cited herein are incorporated herein by reference in their entirety.

[0084] Various embodiments and aspects of the invention described herein are summarized by the following subsections. Item 1. A composition comprising protein nanoparticles containing a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide. Item 2. The composition of Item 1, wherein the fusion protein comprises multiple unstructured polypeptides. Item 3. The composition of Item 1 or 2, wherein the fusion protein comprises multiple targeting polypeptides. Item 4. The composition according to any one of Items 1 to 3, wherein the unstructured polypeptide comprises a diblock peptide. Item 5. The composition of any one of Items 1 to 4, wherein the unstructured polypeptide comprises a diblock of a core polypeptide and a corona polypeptide. Item 6. The unstructured polypeptide is a core n -corona m 6. The composition according to any one of items 1 to 5, wherein n is a repeating number of 20 to 200 and m is a repeating number of 40 to 200. Item 7. The composition of any one of Items 1 to 6, wherein the core polypeptide comprises the sequence QYPSDGRG (SEQ ID NO: 1), GRGDQPYQ (SEQ ID NO: 2), GRGDSPYQ (SEQ ID NO: 3), GRGDSPYS (SEQ ID NO: 4), GRGDQPYS (SEQ ID NO: 5), GRGDSP[3Y:V]S (SEQ ID NO: 6), GRGDSP(Y:V]S (SEQ ID NO: 7), or a combination thereof. Item 8. The composition of any one of Items 1 to 7, wherein the corona polypeptide comprises the sequence VPG[A:G]G (SEQ ID NO: 8), VPGSG (SEQ ID NO: 9), VPGVG (SEQ ID NO: 10), VPQQG (SEQ ID NO: 11), GRGDSPAS (SEQ ID NO: 12), GRGDSPIS (SEQ ID NO: 13), GRGDSPVS (SEQ ID NO: 14), GRGDQPHN (SEQ ID NO: 15), GRGDNPHQ (SEQ ID NO: 16), GRGDSPV (SEQ ID NO: 17), or a combination thereof. Item 9. The core polypeptide has the sequence (RLP) n (SEQ ID NO: 1), wherein n is a repeat number of 20 to 200. Item 10. The composition according to any one of Items 1 to 9, wherein the corona polypeptide comprises the sequence (ELP)m (SEQ ID NO: 8), where m is the number of repeats of 40 to 200.

[0085] Item 11. The diblock, RLP40-ELP40 (SEQ ID NO: 83), RLP40-ELP80 (SEQ ID NO: 84), RLP40-ELP160 (SEQ ID NO: 82), RLP60-ELP80 (SEQ ID NO: 85), RLP80-ELP80 (SEQ ID NO: 87), RLP80-ELP160 (SEQ ID NO: 86), or RLP100-ELP80 (SEQ ID NO: 88) Item 11. The composition according to any one of items 1 to 10, comprising: Item 12. The composition according to any one of Items 1 to 11, wherein the targeting polypeptide comprises a polypeptide of 2 kDa to 100 kDa. Paragraph 13. The composition of any one of paragraphs 1 to 12, wherein the targeting polypeptide comprises a type III domain from human fibronectin (Fn3) (SEQ ID NO: 60), an aFn3 domain from human tenascin C (Tn3) (SEQ ID NO: 62), or the Z domain of Staphylococcus aureus protein A (SEQ ID NO: 64). Item 14. The composition of any one of Items 1 to 13, wherein the targeting polypeptide comprises a type III domain derived from human fibronectin (Fn3) (SEQ ID NO: 60). Item 15. The composition of any one of Items 1 to 14, wherein the targeting polypeptide comprises an Fn3 domain derived from human tenascin-C (Tn3) (SEQ ID NO: 62). Clause 16. The composition of any one of clauses 1 to 15, wherein the targeting polypeptide comprises the Z domain of Staphylococcus aureus protein A having a sequence comprising (SEQ ID NO: 64). Item 17. The composition according to any one of Items 1 to 16, wherein the core polypeptide is crosslinked. Item 18. A protein nanoparticle comprising a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide. Item 19. The protein nanoparticle according to Item 18, wherein the fusion protein comprises multiple unstructured polypeptides. Item 20. The protein nanoparticle according to Item 18 or 19, wherein the fusion protein comprises multiple binding polypeptides.

[0086] Item 21. The protein nanoparticle of any one of Items 18 to 20, wherein the unstructured polypeptide comprises a diblock peptide. Item 22. The protein nanoparticle of any one of Items 18 to 21, wherein the unstructured polypeptide comprises a diblock of a core polypeptide and a corona polypeptide. Item 23. The unstructured polypeptide is a core n -corona m Item 23. The protein nanoparticle according to any one of Items 18 to 22, comprising: Item 24. The protein nanoparticle of any one of Items 18 to 23, wherein the core polypeptide comprises the sequence QYPSDGRG (SEQ ID NO: 1), GRGDQPYQ (SEQ ID NO: 2), GRGDSPYQ (SEQ ID NO: 3), GRGDSPYS (SEQ ID NO: 4), GRGDQPYS (SEQ ID NO: 5), GRGDSP[3Y:V]S (SEQ ID NO: 6), GRGDSP(Y:V]S (SEQ ID NO: 7), or a combination thereof. Item 25. A protein nanoparticle according to any one of Items 18 to 24, wherein the repeating core polypeptide sequence is interspersed with at least 1 to 10 non-classical amino acids selected from azidophenylalanine, acetylphenylalanine, propargyloxyphenylalanine, acetylphenylalanine, or azidohomoalanine. Item 26. The protein nanoparticle of any one of Items 18 to 25, wherein the corona polypeptide comprises the sequence VPG[A:G]G (SEQ ID NO: 8), VPGSG (SEQ ID NO: 9), VPGVG (SEQ ID NO: 10), VPQQG (SEQ ID NO: 11), GRGDSPAS (SEQ ID NO: 12), GRGDSPIS (SEQ ID NO: 13), GRGDSPVS (SEQ ID NO: 14), GRGDQPHN (SEQ ID NO: 15), GRGDNPHQ (SEQ ID NO: 16), GRGDSPV (SEQ ID NO: 17), or a combination thereof. Item 27. The core polypeptide has the sequence (RLP)n Item 27. The protein nanoparticle according to any one of Items 18 to 26, comprising (SEQ ID NO: 1), wherein n is the number of repetitions of 20 to 200. Item 28. The protein nanoparticle of any one of Items 18 to 27, wherein the corona polypeptide comprises the sequence (ELP)m (SEQ ID NO: 8), where m is the number of repeats of 40 to 200. Item 29. The diblock, RLP40-ELP40 (SEQ ID NO: 83), RLP40-ELP80 (SEQ ID NO: 84), RLP40-ELP160 (SEQ ID NO: 82), RLP60-ELP80 (SEQ ID NO: 85), RLP80-ELP80 (SEQ ID NO: 87), RLP80-ELP160 (SEQ ID NO: 86), or RLP100-ELP80 (SEQ ID NO: 88) Item 29. The protein nanoparticle according to any one of Items 18 to 28, comprising: Item 30. The protein nanoparticle according to any one of Items 18 to 29, wherein the targeting polypeptide comprises a polypeptide of 2 kDa to 100 kDa.

[0087] Item 31. The protein nanoparticle of any one of Items 18 to 30, wherein the binding polypeptide comprises a type III domain derived from human fibronectin (Fn3) (SEQ ID NO: 60), an Fn3 domain derived from human tenascin C (Tn3) (SEQ ID NO: 62), or the Z domain of Staphylococcus aureus protein A (SEQ ID NO: 64). Item 32. The protein nanoparticle of any one of Items 18 to 30, wherein the binding polypeptide comprises a type III domain derived from human fibronectin (Fn3) (SEQ ID NO: 60). Item 33. The protein nanoparticle of any one of Items 18 to 30, wherein the binding polypeptide comprises an Fn3 domain derived from human tenascin-C (Tn3) (SEQ ID NO: 62). Item 34. The protein nanoparticle of any one of Items 18 to 30, wherein the binding polypeptide comprises the Z domain of Staphylococcus aureus protein A having a sequence comprising (SEQ ID NO: 64). Item 35. The protein nanoparticle of any one of Items 18 to 30, wherein the binding polypeptide comprises ErbB2 receptor-associated protein (ANHP) (SEQ ID NO: 74). Item 36. The protein nanoparticle of any one of Items 18 to 30, wherein the binding polypeptide comprises a cell-binding peptide (GRGDSPAS) (SEQ ID NO: 76). Item 37. The protein nanoparticle of any one of Items 18 to 30, wherein the binding polypeptide comprises adeno-associated virus (AAV) binding protein (PKD2) (SEQ ID NO: 112). Item 38. The protein nanoparticle of any one of Items 18 to 30, wherein the binding polypeptide comprises an adenovirus (AdV) binding protein (CAR) (SEQ ID NO: 114). Item 39. The protein nanoparticle of any one of Items 18 to 30, wherein the binding polypeptide comprises lentivirus (LV) binding protein (CR2) (SEQ ID NO: 116) or (CR3) (SEQ ID NO: 118). Item 40. The protein nanoparticle of any one of Items 18 to 30, wherein the binding polypeptide comprises albumin binding protein (ABP) (SEQ ID NO: 120).

[0088] Item 41. A protein nanoparticle according to any one of items 22 to 40, wherein the core is covalently crosslinked using a linker compatible with photo or other click chemistry. Item 42. The protein nanoparticle of any one of Items 22 to 41, wherein the core polypeptide is crosslinked. Item 43. The protein nanoparticle according to any one of Items 18 to 42, wherein the nanoparticle encapsulates one or more types of low molecular weight drugs inside the nanoparticle. Item 44. The protein nanoparticle of any one of Items 18 to 43, wherein the fusion protein further comprises a therapeutic protein. Item 45. The protein nanoparticle according to any one of Items 18 to 44, wherein the composition is a therapeutic agent, a targeted delivery agent, a separation agent, or a purification agent. Item 46. A therapeutic agent comprising the protein nanoparticle according to any one of items 18 to 45. Item 47. A method for targeting a therapeutic agent to a cell, comprising administering the protein nanoparticle according to any one of Items 18 to 45. Item 48. A method for delivering a therapeutic agent to a cell, comprising administering the protein nanoparticle according to any one of Items 18 to 45. Item 49. A means for targeting a therapeutic agent to a cell, comprising administering the protein nanoparticle according to any one of items 18 to 45. Item 50. A means for delivering a therapeutic agent to a cell, comprising administering the protein nanoparticle according to any one of items 18 to 45.

[0089] Item 51. A method for identifying a biomolecule, wherein the protein nanoparticles according to any one of items 18 to 45 are added to a solution containing the biomolecule, and the protein nanoparticles specifically bind to the biomolecule. Item 52. A method for purifying a biomolecule, comprising isolating the biomolecule from a culture medium or a complex matrix using a protein nanoparticle according to any one of items 18 to 45 that binds to the biomolecule. Clause 53. The method of Clause 52, further comprising triggering phase separation of the binding polypeptide to isolate the biomolecule from contaminants, wherein the trigger is selected from adjusting temperature, salinity, light, pH, pressure, the concentration of the binding polypeptide or the concentration of the biomolecule, application of electromagnetic or acoustic waves, or addition of one or more excipients including one or more of a cofactor, a surfactant, a crowding agent, a reducing agent, an oxidizing agent, a denaturant, or an enzyme. Clause 54. The method of clause 52, further comprising separating high density phase separated proteins bound to said biomolecules from contaminating biomolecules using centrifugation. Clause 55. The method of clause 52 or 54, further comprising separating phase-separated proteins bound to said biomolecules from contaminating biomolecules using centrifugation. Item 56. The method of any one of items 52 to 55, further comprising isolating the biomolecule from contaminant species using the size of the phase separation droplets, wherein the size of the binding polypeptide bound to the biomolecule is at least 20 nm and no more than 100 μm in diameter. Clause 57. The method of any one of clauses 52 to 56, comprising isolating the biomolecule-binding polypeptide complex from contaminant species based on size using flow filtration, membrane chromatography, analytical ultracentrifugation, high performance liquid chromatography, membrane chromatography, normal flow filtration, sonic separation, centrifugation, counterflow centrifugation, and fast protein liquid chromatography. Item 58. A biomolecule comprising at least one of a lipid, a cell, a protein, a nucleic acid, a carbohydrate, or a virus particle, wherein the nucleic acid is single-stranded or double-stranded DNA or RNA, the virus particle is an adenovirus particle, an adeno-associated virus particle, a lentivirus particle, a retrovirus particle, a poxvirus particle, a measles virus particle, or a herpesvirus particle, and the protein is selected from human albumin, a monoclonal IgG antibody, or an Fc fusion antibody. [Example]

[0090] Example 1 Gene synthesis Plasmid genes for RLP20 (SEQ ID NO: 18-19), RLP20-ELP80 (SEQ ID NO: 81), RLP40-ELP80 (SEQ ID NO: 84), RLP80-ELP80 (SEQ ID NO: 87), RLP100-ELP80 (SEQ ID NO: 88), and the Fn3 domain (SEQ ID NO: 60) that bind to αvβ3 integrin were available from previous studies. These genes were then fused to the gene encoding the Fn3 domain. Similarly, the genes encoding RLP20-ELP80 (SEQ ID NO: 81), RLP40-ELP80 (SEQ ID NO: 84), and RLP80-ELP80 (SEQ ID NO: 87) were cloned into the N-terminus of Fn3 (SEQ ID NO: 60) by directional ligation. After successful confirmation of gene assembly by Sanger fluorescent DNA sequencing, plasmids carrying each construct were isolated and transformed into the BL21(DE3) expression strain of E. coli. Aliquots of the cell stock were stored at −80° C. until further use.

[0091] Protein purification Each block polypeptide was expressed in BL21(DE3) Escherichia coli using a previously published overexpression protocol. A 5 mL bacterial culture was grown overnight from a frozen glycerol stock and used to inoculate a 1 L flask of TB-Dry supplemented with 45 μg / mL kanamycin. The flask was then incubated at 37°C for 24 hours at 190 rpm. Each construct was purified using inverse phase transition cycling (ITC). Briefly, the cell suspension was centrifuged at 3,000 rpm for 10 minutes at 4°C, and the cell pellet was resuspended in PBS and then lysed by sonication on ice for 2 minutes (10 seconds on, 40 seconds off) (Misonix S-4000; Farmingdale, NY). Polyethylenimine (PEI) 0.7% w / v was added to the lysate to precipitate nucleic acid contaminants. The supernatant was then passed through multiple rounds of ITC as follows: the solution was kept on ice, and 3 M NaCl was added to isothermally trigger the phase transition of the RLP-ELP block copolypeptide. The coacervate was then centrifuged at 14,000 × g for 20 minutes at 30 °C, the supernatant was decanted and discarded, and the pellet was resuspended in phosphate buffer. The lysate was cooled to 4 °C and then centrifuged at 15,000 × g for 10 minutes at 4 °C to remove insoluble contaminants. To remove excess salt from the purified protein solution, the sample was dialyzed against ddH2O for at least 24 hours at 4 °C using a Spectrum™ Labs Spectra / Por™ 2 12-14 Standard RC Dry Dialysis Kit (Fisher Scientific, Waltham, MA). The protein was then lyophilized and stored at -20 °C. The purity of the block polypeptide was assessed by SDS-PAGE gel staining with SimplyBlue.

[0092] Characterization of phase separation Temperature-dependent UV-visible spectrophotometry Turbidity profiles were obtained for each construct by recording the optical density as a function of temperature (1°C / min ramp) on a temperature-controlled UV-visible spectrophotometer (Cary300Bio; Varian Instruments; Palo Alto, CA). The transition temperature (T t) was defined as the inflection point of the turbidity profile. Samples were measured at 10 μM in PBS. Because some of the block copolypeptides, which form larger micelles when soluble, were slightly turbid, all measurements were performed after zeroing with PBS.

[0093] Static and dynamic light scattering Static and dynamic light scattering (SLS / DLS) measurements were performed using an ALV / CGS-3 goniometer system (Langen, Germany). Samples for the ALV / CGS-3 goniometer system were prepared at a concentration of 10 μM in PBS and filtered through a 0.45 μm Millex-GV filter into a 10 mm disposable borosilicate glass tube (Fischer). Simultaneous SLS and DLS measurements were performed at 15°C for ELP at angles ranging from 30° to 150° in 5° increments, with each angle consisting of three 15-second runs. SLS experiments were performed using a single block copolypeptide chain with known molecular weights and a single R chain. g was only performed on the self-assembling block copolypeptides because the differential refractive index (d n / d c The hydrodynamic radius (R) was determined by measuring the refractive index at different concentrations using an Abbemat500 refractometer (Anton Paar, Graz, Austria). DLS data were analyzed by fitting the autocorrelation function to a cumulant fit using the built-in ALV software. h ) was plotted against the angle and extrapolated to zero. g and SLS data were analyzed by partial Zimm plots using ALVSTAT software to determine molecular weight (MW).

[0094] Temperature-programmed dynamic light scattering Temperature-programmed dynamic light scattering experiments were performed using a DynapRo plate reader (Wyatt Technology; Santa Barbara, CA) with samples filtered through a 0.45 μm Millex-GV filter. Data were collected in 1°C increments, and the radii were determined as cumulant-fit hydrodynamic radii. t was defined as the temperature at which aggregates with a size of several hundred nanometers were formed.

[0095] Cryo-transmission electron microscopy Cryo-TEM experiments were performed at Duke University's Shared Materials Instrumentation Facility (Durham, NC). Lace-hole carbon grids (Ted Pella, Redding, CA) were glow-drained in a PELCO EasiGlow Cleaning System (Ted Pella, Redding, CA). A 3 μL drop (10 μM RLPn-ELP80) was deposited onto the grid, blotted at an offset of -3 mm for 3 seconds, and vitrified in liquid ethane using a Vitrobot Mark III (FEI, Eindhoven, The Netherlands). Prior to vitrification, the sample chamber was maintained at 15 °C and 100% relative humidity to prevent sample evaporation. Grids were transferred to a Gatan 626 cryoholder (Gatan, Pleasanton, CA) and imaged on an FEI Tecnai G2 Twin TEM (FEI, Eindhoven, The Netherlands) operating at 80 keV. Feature size and spacing distance were measured by manually measuring at least 25 particles in ImageJ.

[0096] Surface plasmon resonance spectrophotometry Surface plasmon resonance experiments were performed using a Biacore T200. Purified human αvβ3 integrin (Chemicon, Temecula, CA) was immobilized on a research-grade CM5 sensor chip using an amine coupling kit (BIAcore, Piscataway, NJ). The integrin was diluted in 10 mM sodium acetate buffer (pH 4.5) and conjugated to a surface density of approximately 600 resonance units (RU). Binding events were measured using block copolypeptide concentrations ranging from 2.5 to 10 μM. Block polypeptides were diluted in HBS-P buffer (10 mM HEPES, 140 mM NaCl, 0.005% Triton-X, pH 7.4) supplemented with 2 mM CaCl2 and delivered at 30 μL min. -1 The complexes were allowed to dissociate for 10 minutes. The surface was then washed with 10 mM glycine-HCl (pH 2.5) at a flow rate of 30 μL min−1. -1 for 45 s, followed by 10 mM glycine-HCl (pH 2.0) at a flow rate of 30 μL min -1 The surface was regenerated with 10 mM glycine-HCl (pH 2.0) for 30 seconds. Kinetic modeling and simulations were performed using BIAevaluation software, using a heterogeneous ligand model for the self-assembling protein and a 1:1 ligand model (RLP20-ELP80-Fn3) for the unimeric protein. The equilibrium binding constant (K D1 and K. D2 ) as the kinetic dissociation rate (k off ) to the association rate (k on ) and calculate the average K D1 / 2 All SPR measurements were performed at 25°C. SPR measurements were performed using polypeptide concentrations ranging from 2.5 to 10 μM. The goodness of fit was assessed by analyzing the residual plots and residual sums of squares.

[0097] Flow cytometry Approximately 1×10 6Cells were harvested from either K562 or K562+αvβ3 cell lines and resuspended in 1 mL of serum-free medium containing 10 μM of various Fn3-decorated and control blocking polypeptides. LM609 antibody was also resuspended at 10 μM in serum-free medium. Micelles were prepared from a mixture of approximately 10% Alexa488 dye-labeled RLP-ELP block copolypeptide and 90% unlabeled polypeptide on a molar basis. Cells were incubated with the labeled micelles at 37°C for the indicated time, then rinsed with 1 mL of Hanks' buffered saline (HBSS), collected by centrifugation at 500 RCF for 5 minutes at 20°C, and resuspended in HBSS + 1% BSA. Cells were kept on ice until analysis by flow cytometry (BD Accuri C5). Alexa488 (green) cellular fluorescence intensity was quantified after gating to remove cellular debris on unstained control samples.

[0098] Confocal microscope Approximately 1×10 6 Cells were harvested from either K562 or K562+αvβ3 cell lines and resuspended in 1 mL of serum-free medium containing 10 μM of various modified and unmodified blocking polypeptides. Cells were incubated at 37°C for various times (20–240 min). After three washes with HBSS, 20 μL of cell suspension was added to a 384-well plate with a #1.5 coverslip at the bottom. Cells were imaged using a 40x oil immersion objective on a Zeiss 710 inverted confocal microscope (Oberkochen, Germany) equipped with a live-cell chamber maintained at 37°C.

[0099] Confocal image analysis To analyze the percentage of cells showing polypeptide uptake, the fluorescence and DIC channels were isolated and analyzed independently. In the fluorescence channel, the bottom 10% of cellular fluorescence was removed to eliminate autofluorescence from naive K562 cells. Using this cutoff, the location and area of ​​green fluorescence were identified using only the fluorescence channel. The DIC channel was then used to count the total number of cells.

[0100] Fluorophore labeling The N-terminus and lysine residues in the RLP-ELP-Fn3 fusion were labeled with an NHS-ester derivative of Alexa488. To bias the reaction toward N-terminal labeling, the pH of the reaction mixture was adjusted to 8.3. The RLP-ELP block copolypeptide dissolved in 0.1 M sodium bicarbonate buffer (pH 8.3) was added with a molar excess of dye (dye:protein molar ratio depending on the total number of reactive groups in the protein, including lysine residues and the N-terminus (e.g., dye:RLP)). 20 =2:1, dye:RLP 20 The mixture was incubated with 1:500 (v / v) of 1000-Fn3 (5:1) at room temperature with continuous stirring for 2 hours. Excess dye was removed by dialysis against Milli-Q water at a volume ratio of 1:500 for three rounds at 4°C over three days. The samples were lyophilized and stored at -20°C.

[0101] Example 2 Block copolypeptides with UCST and LCST phase behavior can be combined to generate micelles with predictable nanoscale assemblies. The first area of ​​investigation was the effect of the hydrophilic mass fraction of the RLP-ELP block copolypeptide. The core block sequence was (Gln-Tyr-Pro-Ser-Asp-Gly-Arg-Gly)-XX (RLPXX) (SEQ ID NO: 1), and the corona sequence was (Val-Pro-Gly-[Ala / Gly]-Gly)-YY (ELPYY) (SEQ ID NO: 8), with a 50 / 50 guest ratio between Ala and Gly. The size of the core block was controlled to be 20, 40, 60, or 80 repeat units of (Gln-Tyr-Pro-Ser-Asp-Gly-Arg-Gly), and the corona block was 80 repeats of (Val-Pro-Gly-[Ala / Gly]-Gly)-YY (SEQ ID NOs: 81, 84, 93, 87).

[0102] Scattering experiments provide insight into several details about the assembly of these polypeptides (Table 1). First, RLP20-ELP80 does not self-assemble because it follows a completely soluble polymer chain of approximately 47 kDa with a hydrodynamic radius of 5.5 nm. Second, both RLP40-ELP80 and RLP60-ELP80 self-assemble. h is less than 50 nm, R g They self-assemble into structures with radiuses less than 40 nm, shape factors less than 1, and aggregation numbers less than 250. The combination of radius, shape factor, and aggregation number indicates that both RLP40-ELP80 and RLP60-ELP80 likely self-assemble into spherical micelles. Third, RLP80-ELP80 self-assembles into much larger structures with hydrodynamic radii greater than 100 nm, radii of gyration greater than 140 nm, shape factors of approximately 1.2, and aggregation numbers of several thousand chains. These results indicate that RLP80-ELP80 self-assembles into much larger, non-spherical structures.

[0103] [Table 1] Cryo-TEM results confirm the doubts raised by both dynamic and static light scattering (Figure 4). Some key observations for all constructs are that the nanostructures are in close spatial proximity to each other, indicating that these structures are in a near-overlap regime. Sample preparations were theoretically at 10 µM, in the dilute regime. Thus, the concentration of these structures is artificially increased by the vitrification process.

[0104] However, increasing the preparation concentration of RLP40-ELP80 to 100 μM and 1 mM did not appear to affect the structure observed by cryo-TEM (Figure 5). Therefore, we expect that the self-assembled morphology will have a wide range of concentration independence, and that the shapes observed by cryo-TEM will be consistent with the light scattering data. Finally, we were unable to visualize corona chains for any of the RLP-ELPs sampled, likely due to the high water content and poor contrast with water.

[0105] Both RLP40-ELP80 (SEQ ID NO: 84) and RLP60-ELP80 (SEQ ID NO: 93) (Figure 4) self-assemble into spherical micelles. This result was suggested by DLS data and SLS and confirmed by cryo-TEM. Measurements of the core radii show that the RLP40-ELP80 (SEQ ID NO: 84) and RLP60-ELP80 (SEQ ID NO: 93) cores are approximately 12.8 nm and 17.5 nm, respectively, consistent with larger core-building blocks leading to larger micelle cores. This indicates that R h and R g This is consistent with the larger values ​​reported by light scattering, since only the micelle core is directly observed by cryo-TEM, whereas the micelle core is incorporated into both the core and corona of the micelle. The spacing is similar for both at 29.5 nm, which is consistent because both block copolypeptides have the same morphology and the same corona-forming ELP block.

[0106] Cryo-TEM reveals that RLP80-ELP80 (SEQ ID NO: 87) (Figure 4) forms distinct nanostructures. These block copolypeptides form long cylindrical structures. Again, the apparent increase in core block size from 17.5 nm to 19.9 nm and the increase in spacing from 28.9 nm to 34.7 nm are consistent with the increased core block size (although the increase in core size is not significant). These overlapping structures are more consistent with lamellar formation; therefore, at this concentration, the aspect ratio of the cylinders is not observable by cryo-TEM.

[0107] [Table 2] To test whether the total hydrophilic mass fraction or block length was the primary driving force for micellar formation, we varied the total length while maintaining a specific hydrophilic mass fraction, resulting in a comparison of the total hydrophilic mass fractions of 64.7% (RLP20-ELP80 (SEQ ID NO: 81) and RLP40-ELP-160 (SEQ ID NO: 82)), 47.4% (RLP20-ELP-40 (SEQ ID NO: 80), RLP40-ELP80 (SEQ ID NO: 84), and RLP80-ELP-160 (SEQ ID NO: 86)), and 30.9% (RLP40-ELP-40 (SEQ ID NO: 83) and RLP80-ELP80 (SEQ ID NO: 87)).

[0108] As previously mentioned, RLP20-ELP80, which has a hydrophilic mass of 64.7%, did not assemble. However, doubling the block length of the corona and core (RLP40-ELP160) (SEQ ID NO: 82) resulted in R g is 70.8nm, R h The aggregates had a diameter of 92.3 nm and a shape factor of 0.8, indicating a spherical micellar morphology. This result was confirmed by cryo-TEM, which revealed spheres with an average core radius of 11.0 nm and a core-to-core spacing of 22.3 nm.

[0109] [Table 3] Both RLP20-ELP40 (SEQ ID NO: 80) and RLP80-ELP160 (SEQ ID NO: 86) are expected to assemble into spherical micelles due to the 47.4% total hydrophilic mass fraction exhibited by spherical micelles with RLP40-ELP80 (SEQ ID NO: 84). However, RLP20-ELP40 did not assemble, instead producing soluble RLPs of 5.3 nm, consistent with 32 kDa chains. h This can be explained as a 32 kDa chain that does not have a sufficient assembly domain size. RLP80-ELP160 (SEQ ID NO: 86)g is 78.2nm, R h assembles at 93.3 nm and a shape factor of 0.8, exhibiting spherical micelles.

[0110] Cryo-TEM imaging confirmed this result and provided interesting nanostructural information (Figure 6). The cores of these micelles had a radius of 29.3 nm, with an intracore spacing of 59.0 nm. This core dimension is much larger than that of RLP80-ELP80 (SEQ ID NO: 87), which adopted cylindrical micelle formation, indicating that the larger spherical cores are more expanded in spherical micelles than in cylindrical micelles. This result could be directly predicted from the theory of synthetic polymer micelles, since the spherical chains are expected to be elongated rather than in a rod-like conformation. Additionally, much larger intracore spacing is observed due to the doubling of the size of the ELP chains.

[0111] [Table 4] Finally, RLP40-ELP40 (SEQ ID NO: 83) g is 56.2nm, R h The core radius (11.8 nm) and spacing (19.5 nm) are both smaller than those of the larger polymers, consistent with smaller core and corona chains. The core size is approximately the same as that of other aggregates with different morphologies.

[0112] Another important design parameter besides the effect of hydrophilic mass fraction is the effect of corona hydrophilicity. Therefore, we substituted the more hydrophobic guest residue Val (V) and the more hydrophilic guest residue Ser (S) into RLP40-ELP80, RLP60-ELP80, and RLP80-ELP80 (SEQ ID NOs: 89–94). Our hypothesis is that the introduction of Val reduces corona chain repulsion, leading to a more globular to more rod-like assembly. Ser would result in more chain repulsion, driving the rod-to-globular transition.

[0113] Substitution of Ala / Gly with Val results in a shift in light scattering data from spherical to worm-like (Table 5). Comparing RLP40-ELP80 (SEQ ID NO: 84) (spherical) and RLP40-ELPV80 (SEQ ID NO: 92), RLP40-ELPV80 (SEQ ID NO: 92) had a higher number of aggregates and R g The value increases, resulting in ρ>1. Since these two polymers have nearly identical molecular weights and identical chain lengths, it can be inferred that RRLP40-ELPV80 (SEQ ID NO: 92) forms a more elongated structure. A similar increase is seen for RLP40-ELPV80 compared to RLP40-ELP-80 (SEQ ID NO: 84). Similar to the Ala / Gly construct, N agg , R g , and R h increases with increasing core block length, but the shape factor remains >1, indicating that all Val constructs are worm-like micelles.

[0114] [Table 5] On the other hand, RLP40-ELPS80 (SEQ ID NO: 89) has almost the same N as RLP40-ELP80 (SEQ ID NO: 84). agg , R g and R h This would indicate that both constructs are spherical micelles. Interestingly, the substitution of serine for alanine and glycine in RLP80-ELP80 results in Nagg , R g , R h This would decrease the morphology of the N-terminal amino acid sequence, resulting in a shape factor of less than 1. This would indicate that this substitution resulted in a shift in morphology from worm-like micelles to globular structures. Similar to the Ala / Gly and Val constructs, the N-terminal amino acid sequence agg , R g , and R h increases with increasing core block length, but the shape factor remains below 1, indicating that all serine constructs are globular.

[0115] As suspected by the light scattering data, the substitution of Ala / Gly with Val resulted in a shift from spherical to worm-like micelles according to cryo-TEM imaging. In Figure 7, we see that with increasing hydrophilic mass fraction, the worms become progressively longer, but the core radius remains roughly the same size (Table 6), ultimately resulting in an interconnected network. The substitution of Ala / Gly with Ser appears to increase corona repulsion to the point that only spherical micelles can form.

[0116] [Table 6] In addition to making changes to the corona sequence that increase or decrease interchain repulsion (or perhaps alter the chain volume occupied), we attempted the same experiment, this time on the core sequence. Previous studies have shown that substituting Val for Tyr increases the saturation concentration and decreases the density of the dense phase. Therefore, we hypothesized that this same substitution would have a similar effect on the particle core, increasing or decreasing the core volume occupied and possibly altering the self-assembly structure. We mutated the RLP40-ELP80 (SEQ ID NO: 84) and RLP80-ELP80 (SEQ ID NO: 91) core repeat sequences, replacing (QYPSDGRG) (SEQ ID NO: 1) with (GRGDSP[Y]S) (SEQ ID NO: 6-7), and systematically substituted Val for Tyr in the new repeat units. We observed that systematic substitution of Tyr along the backbone resulted in a transition from a more spherical particle to a more elongated, scattering structure for both core molecular weights (Figure 8). Specifically, at a core repeat number of 80, we observe spherical micelles or lamellae and vesicle structures that transition to all three transition states, wormlike micelles. Notably, the vesicle structures appear to be in two-phase equilibrium with the wormlike structures, due to the presence of additional contrast regions across various cryo-TEM imaging frames. The assembly of these vesicles is also quite extensive, with various shapes, sizes, and multilayer structures simultaneously forming, despite the monodispersity of the repeating units.

[0117] In addition to altering the block architecture, another factor that can affect the assembly of these dynamic molecules is the quality of the solvent. A dramatic example of this effect can be seen in Figure 9, where changing the buffer of (GRGDSP[Y:V]S)80-ELP80 (SEQ ID NO: 110) from 140 mM PBS to water, a poor solvent for the core and a good solvent for the corona, changes the assembly from vesicles / worm-like micelles to spherical micelles. This is further evidence supporting our hypothesis that changes in chemical sequence affect chain volume, and therefore altering hydrophobicity also leads to physical modifications at the chain level.

[0118] All of these modifications to the core and corona chains prompted us to measure the critical micelle concentration (CMC) of these micellar constructs. Therefore, we employed a well-developed technique in our laboratory to measure the CMC of encapsulated pyrene within the particle core. Depending on the solution polarity, pyrene exhibits distinct fluorescence signals in peaks 1 and 3 (I1 and I3). At concentrations above the CMC, pyrene is sequestered by the particle core, modulating this I1 and I3 ratio. For RLP40-ELP80 (SEQ ID NO: 84) and RLP80-ELP80 (SEQ ID NO: 91), we approximate a CMC of 100-500 nM, according to the decreasing I1 / I3 ratio (Figure 10), suggesting that these micelles are slightly more stable than previously measured block copolypeptides. Interestingly, tabulating this I1 / I3 ratio for various solvents suggests that the polarity of the particle interior is closer to acetone (1.4) than water (1.8). Therefore, we hypothesized that these micelles could sequester hydrophobic moieties similar to those of block copolymer micelles. To this end, we designed a series of RLP40-ELP80 proteins with similar assembly dimensions but different core chemistries. For the core sequences, we selected (GRGDSPYS) (SEQ ID NO: 24), (GRGDSPYQ) (SEQ ID NO: 22), and (GRGDQPYQ) (SEQ ID NO: 20), all of which have similar UCST binodal lines but contain various uncharged polar residues that can form H-bonds with drugs with different strengths. For the small molecule drug, we selected paclitaxel, which is insoluble in aqueous solvents and suffers from side effects related to its delivery vehicle.

[0119] Using these particles, polypeptide chains were incubated overnight at 4°C in the presence of a 10x molar excess of paclitaxel (PTX) in HO or a 30% acetone + HO mixture, and soluble assembled micelles were maintained in the presence of a large excess of insoluble PTX (Figure 12). Next, the insoluble PTX in the HO sample was centrifuged, and the acetone was dialyzed into Milli-Q HO. The insoluble PTX after dialysis was also removed by centrifugation. 100% acetonitrile was then added to a final concentration of 30% v / v to completely dissolve the micelles and resuspend the PTX into a homogenous mixture of PTX + protein. This sample was then analyzed by C 12 The protein and PTX peaks are separated by analytical HPLC. Using the relative sizes of the PTX and protein peaks at 230 nm and 275 nm, respectively, and the known extinction coefficients, the molar ratio of PTX to protein that remained soluble after subtraction from the non-vehicle control can be determined. Essentially, this experiment demonstrates the extent of increased PTX solubility in the presence of various micellar systems. This increase in suspension concentration is presumably due to sequestration in the particle core.

[0120] The results support the conclusion that various RLP-ELP micelles can increase the observed solubility of PTX in normally unsuitable solvents. When acetone was used as a cosolvent, a dramatic increase in loading capacity was observed due to its ease of diffusion into the particle core, which has a similar polarity to acetone. We also observed dramatic differences between subtle particle chemistries, suggesting that the primary amino acid sequence can control this partitioning factor by 2-3 fold (Figures 11 and 13). In the best-performing case, 100% Gln substitution for Ser, we observed PTX / protein molar ratios corresponding to similar conjugation efficiencies achieved with PTX versus protein (approximately 8 PTX per protein chain in the 100% Gln substitution case). Therefore, we suggest that this physical loading procedure may offer an alternative delivery scheme in contrast to direct chemical conjugation to Lys or Cys residues.

[0121] Example 3 Block copolypeptides with UCST and LCST phase behavior can be combined for multivalent presentation of protein and peptide ligands Using this RLP-ELP block copolypeptide platform, we attempted to develop micelles capable of multivalent presentation. We selected the tenth type III domain from human fibronectin (Fn3) as the targeting domain, which targets the human αvβ3 integrin. This domain is a receptor that is upregulated in the endothelium of many tumors and is overexpressed in several tumor cells, including glioblastoma, renal cell carcinoma, ovarian cancer, and breast cancer metastases. We used low-affinity (K D >1×10 -7 We selected Fn3 variants that bind to αvβ3 integrin (M) and can be expressed in E. coli as fusions to repeat polypeptides such as ELP. The low affinity of the parent Fn3 domain is important because multivalent presentation can amplify its avidity, which may not be possible with ligands with inherently high affinity, allowing us to test the effects of self-assembly and multivalency on binding avidity and cellular uptake.

[0122] After assembly of the genes in the expression vectors, each vector was transformed into the BL21(DE3) strain of E. coli and overexpressed according to a previously published protocol. Block copolypeptides were isolated from the soluble fraction of cell lysates and purified by inverse phase cycling, a non-chromatographic method, to a purity of >95% as measured by SDS-PAGE (Figure 14). Yields of all polypeptides were >20 mg L without any optimization of the expression protocol. -1 Shaker flask cultures were typically 5–20 mg L−1. -1 is.

[0123] Each block copolypeptide was analyzed by dynamic light scattering (DLS) at several temperatures between 4 °C and 37 °C to determine the thermal stability of the micelles and their hydrated radius (R h The R of RLP20-ELP80 (SEQ ID NO: 81) and RLP20-ELP80-Fn3 (SEQ ID NO: 95) was determined.h is about 7 nm, and its R h is that of denatured proteins with similar molecular weights and other elastin-like polypeptides of similar size (R h 8 nm), indicating that these constructs do not assemble within this temperature range and exist as soluble disordered polypeptides. In contrast, RLP40-ELP80 (SEQ ID NO: 84) and RLP40-ELP80-Fn3 (SEQ ID NO: 96) exhibited R of 30 and 32 nm, respectively, between 20 and 37 °C. h It self-assembled into micelles (Figure 15). Similarly, RLP80-ELP80 (SEQ ID NO: 87) (112 nm) and RLP80-ELP80-Fn3 (SEQ ID NO: 97) (47 nm) formed stable micelles over the same temperature range (Figure 16). Interestingly, the RLP80-ELP80 (SEQ ID NO: 87) h is dramatically affected by the presentation of the Fn3 domain on the hydrophilic C-terminus of the block copolypeptide (Table 7).

[0124] [Table 7] This result makes sense because RLP80-ELP80 (SEQ ID NO: 87) resides at the edge of the phase boundary separating spherical and worm-shaped micelles. Therefore, incorporating a small, folded protein could potentially result in a change in shape. Furthermore, the RLP40-ELP80-Fn3 (SEQ ID NO: 96) R h The Fn3 domain does not appear to be stable at temperatures above 37°C, as there is a rapid increase in Fn3. Based on this result, samples were kept on ice before flow cytometry and confocal microscopy.

[0125] From previous results, R in the range of 30–40 nm h Micelles with R are likely to be spherical, while micelles with R hWe speculated that micelles >100 nm are likely to be cylindrical or worm-like in structure. We estimated the morphology of these particles and their aggregation number (N agg Next, static light scattering (SLS) measurements were performed to calculate the radius of gyration (R ) per micelle. Increasing the size of the core-forming block (QYPSDGRG) (SEQ ID NO: 1) from 40 to 80 repeats resulted in an increase in the radius of gyration (R ). g ) from 29nm to 39nm, R h from 29nm to 49nm, N agg increases from 201 to 630 chains (Table 7 & Figure 17).

[0126] These results suggest that larger particles have a higher aspect ratio than smaller particles. Unfortunately, the shape factor (ρ = R g / R h The SLS results were inconclusive because ρ (ρ) did not change dramatically between particles with putatively different morphologies. Typically, ρ depends on the particle morphology, with typical values ​​for spheres around 0.7, and increases as the scattering molecules become more elongated (i.e., disk-shaped, cylindrical structures). Therefore, we next directly visualized the particles in a cryo-TEM to confirm their morphology.

[0127] Previous studies of ELP-based micelles have demonstrated that the desolvated core of the micelles can be visualized by cryo-TEM, as it has significant differentiation contrast over the surrounding water, whereas the corona is too solvated to be visualized. We previously reported that increasing the size of the core-forming RLP block from 40 to 80 units without the Fn3 domain (Figure 18A, B, respectively) resulted in a morphology transition from spherical micelles to wormlike micelles. The cores of these micelles increased in diameter from 24 nm to 59 nm, and the interparticle spacing changed from 27 nm to 42 nm, indicating elongation of the corona ELP chains (Table 8). RLPXX-ELP80-Fn3 (sequence numbers 95–97) behaved similarly. Increasing the core size increased the core diameter of the micelles from 27 nm to 51 nm and the core spacing from 27 nm to 42 nm (Figure 18C, D, respectively).

[0128] [Table 8] Image analysis suggests a shift toward assembly, as RLP40-ELP80-Fn3 (SEQ ID NO: 96) has over 90% particles with an aspect ratio <2, while RLP80-ELP80-Fn3 (SEQ ID NO: 97) has 45% micelles with an aspect ratio <2 (Figure 19).

[0129] These results both indicate a morphology shift from spherical micelles to a mixture of spherical and wormlike micelles. These results also support the DLS and SLS experimental measurements, which show that increasing the core block length elongates the micellar morphology, increasing the chain density in the corona, while maintaining the overall shape of the parent block copolypeptide. Next, surface plasmon resonance (SPR) was used to characterize the avidity of RLPXX-ELP80-Fn3 (SEQ ID NOs: 95-97) fusions for the ectodomain of human αvβ3 integrin. SPR sensorgrams were generated for binding of Fn3-functionalized RLP-ELP80 block copolypeptides at concentrations ranging from 2.5 to 10 μM. Kinetic association and (k on ) and dissociation constant (k off ) is summarized in Figure 20. As the size of the core block increases, k on As the magnitude of k increases, off The size of the Fn3-decorated spherical micelles decreased, both of which are consistent with an increase in the size of the binding unit (unimer or larger diameter micelles). As seen in previous studies, Fn3-decorated spherical micelles exhibited a 10-fold increase in avidity for αβ integrin compared to the RLP20-ELP80-Fn3 (SEQ ID NO: 95) construct, which does not self-assemble and therefore displays only a single copy of the Fn3 domain. Interestingly, elongating the particles from a spherical to a worm-like geometry increased the avidity for the integrin by approximately 1000-fold compared to the monomeric ligand, allowing avidity to be driven into picomolar concentrations (Figure 20). This result supports a K in the micromolar range for αβ integrin.D This is remarkable given the non-optimal nature of Fn3, which has an effective K D In fact, the K of approximately 20 nM D This is several orders of magnitude lower than the clinically relevant therapeutic antibody, LM609, which has a binding constant of 0.05%. For context, these binding constants are at the upper threshold for antibodies used for targeted cancer therapeutic targeting, highlighting their clinical relevance.

[0130] To assess the cellular uptake of these particles, a cell line stably transfected with αvβ3 integrin was used. The native cell line K562 served as a receptor-negative control due to its endogenous low expression level of this receptor, and undecorated RLPXX-ELP80 micelles served as a ligand-negative control for the various micelles—sizes and shapes. Cells were incubated with 10 μM solutions of the various block copolypeptides for 2 hours at 37°C. This concentration was determined to be the CMC and K for all micelles. D Confocal microscopy was first used to study the internalization of block copolypeptides by αvβ3 integrin-transfected cell lines. Ligand-negative spherical micelles showed low levels of uptake, whereas ligand-negative worm-like micelles showed slightly higher levels of uptake, consistent with previous observations that they play a role in controlling nonspecific uptake of nanoparticles (Figure 21A).

[0131] However, a much more dramatic difference was observed for Fn3-decorated micelles: compared with parental spherical micelles, which showed a low level of uptake slightly above the level of autofluorescence of the WT-untransfected cell line (Figure 21A), displaying the Fn3 domain on the spherical micelle-forming RLPXX-ELP80 block copolypeptide significantly increased its uptake, as quantified by the number of particles in the cell membrane (Figure 21B) and the mean fluorescence of the cells (p<0.001, unpaired Student's t-test).

[0132] Similarly, the Fn3 ligand-decorated worm-like micelles showed much higher levels of cellular uptake compared to the parent worm-like micelles (Figure 22). In contrast, without overexpression of αvβ3 integrin on K562 cells, the levels of internalization and uptake of spherical and Fn3-decorated micelles were low, indicating that most of the internalization of the ligand-decorated micelles was driven by ligand-receptor engagement (Figure 23).

[0133] The LM609 antibody exhibited a completely different cellular uptake than RLP-ELP80-Fn3 micelles: although it possessed high levels of fluorescence (Figure 22), much of the fluorescence was localized to the cell membrane, and the level of intracellular fluorescence was much lower compared to Fn3-decorated micelles, indicating that this antibody-integrin binding event did not trigger internalization. Next, cellular uptake was quantified using flow cytometry. Unstained K562 cells had a cellular fluorescence background of 2912 ± 3236 (geometric mean ± standard deviation). When incubated with RLP40-ELP80 (SEQ ID NO: 84) spherical micelles, this increased to 8686 ± 8787, and for RLP80-ELP80 spherical micelles, it increased to 24904 ± 13884 (Figure 24), indicating a low level of shape-dependent nonspecific uptake of micelles (p < 0.001, unpaired Student's t-test) (Figure 3B).

[0134] The positive control, LM609 antibody, had a statistically significantly higher uptake of 36,708 ± 255,175, consistent with its known specificity for αvβ3 integrin (Figure 25). A closer look at the flow cytometry data indicates the presence of high- and low-level receptor-expressing cell populations, as seen by the two distinct peaks in Figure 24. Interestingly, spherical micelles formed by RLP40-ELP80-Fn3 (SEQ ID NO: 96) and worm-shaped micelles formed by RLP80-ELP80-Fn3 (SEQ ID NO: 97) have geometric fluorescence intensity means of 15,539 ± 286,229 and 71,382 ± 251,919, respectively, two- and three-fold greater than the undecorated controls (Figure 24).

[0135] Clearly, receptor-mediated endocytosis is shape-dependent, as seen by the significantly higher cellular uptake exhibited by worm-shaped micelles compared to spherical micelles, consistent with their higher avidity for integrins. Fn3-decorated spherical and worm-shaped micelles also showed only a single flow cytometry peak, unlike LM609, which has a bimodal distribution of cellular uptake. This result likely implies that high-density micelles are not affected by heterogeneity in receptor expression, as long as receptor expression exceeds a certain threshold that allows multiple ligands to engage the receptor on the cell surface. Therefore, high-density micelles may offer a more robust strategy than antibodies for targeting cells with heterogeneous levels of receptor expression.

[0136] Morphology appears to be more important than size, as worm-like micelles with the same hydrophilic mass fraction as RLP80-ELP80-Fn3 (SEQ ID NO: 97) but smaller size exhibit higher levels of cellular uptake than comparable-sized spherical micelles of RLP40-ELP80-Fn3 (SEQ ID NO: 96) (Figure 27). Similarly, spherical particles of similar size to the worm-like micelles of RLP80-ELP80-Fn3 (SEQ ID NO: 97) exhibit very low levels of uptake (Figure 26). These data indicate that the elongated shape and flexibility of the worm-like micelles increased the number of accessible Fn3 ligands available for receptor binding. We next visualized the kinetics of internalization by imaging cells at 20, 45, 90, 120, and 240 minutes after incubation (Figure 28). Particle and area analysis of Alexa488 dye was performed on all cells in the field for at least three separate images, resulting in approximately 50 individual measurements for each sample. To eliminate non-internalized regions of fluorescence, the analysis area was gated to exclude the cell membrane.

[0137] The LM609 antibody remained mostly associated with the cell membrane, with a few isolated fluorescent foci within the cells at later time points, whereas the spherical (RLP40-ELP80-Fn3) (SEQ ID NO: 96) and worm-like micelles (RLP80-ELP80-Fn3) (SEQ ID NO: 97) were internalized more quickly, resulting in more particles within the cells at all time points (Figure 29A). Using a three-way ANOVA on time, shape, and decoration condition (Fn3±), we observed main effects of shape, decoration condition, and time on both the number of particles within cells and the area they covered. Pairwise interactions indicate that micelle shape significantly affected the number of particles per cell between spherical and worm-like micelles (p<0.01) and between spherical micelles and the positive antibody control (p<0.05). There were also differences in the area occupied by these particles within cells over time between spherical micelles and the antibody control (p<0.05) and between worm-like micelles and the antibody control (p<0.05) (Figure 29B). There was no significant difference in particle area between spherical and worm-like micelles over time. The overall percentage of the cell population that contained fluorescent signal was assessed, but no significant effect occurred over time. The only significant effects of this ANOVA were the pairwise effects of micelle shape over time (p<0.001) and decoration condition over time (p<0.01). Collectively, these data demonstrate the following: (1) there is a statistically significant increase in cellular uptake with respect to particle morphology, and (2) there is a statistically significant increase in cellular uptake with micelles displaying the integrin-binding Fn3 domain.

[0138] Example 4 Two UCST protein blocks leading to nanoscale self-assembly Given the large library of previously generated RLPs and the large differences in transition temperatures observed, we set out to create the first block copolypeptide made from two UCST blocks. Previous work on ELP block copolypeptides and RLP-ELP block copolypeptides has shown that there is a large difference in the transition temperatures of the two blocks because each block influences the other, driving the transitions of each block closer together. First, we investigated the T t Two RLPs with large differences in their molecular mass were fused: (GRGDSPYS)[S],[S]-40,80 (SEQ ID NOs: 100-101) and GRGDQPHN([QHN]-40). The block length of the core-building block was varied because previous experiments had shown the importance of the overall hydrophilic mass fraction to the assembled morphology. The core block was also varied by changing GRGDQPHN to GRGDNPHQ([NHQ]-40) (SEQ ID NOs: 102-103). This is a hydrophobic change, but maintains the same overall polypeptide composition.

[0139] The first notable observation is that the choice of these two RLP sequences resulted in variable self-assembly. RLPSS-40-RLPQHN-40 (SEQ ID NO: 100) g is 35.1 nm, R h is 28.4 nm, and N agg 43 assembled into identifiable nanoscale morphologies (Table 9). g / R h ) suggests that [S]-40-[QHN]-40 (SEQ ID NO: 100) assembles into worm-like micelles. By increasing the molecular weight of the core block, R g , R h , N agg is dramatic に [S]-80-[QHN]-40 (SEQ ID NO: 101) has a form factor greater than 1, indicating that [S]-80-[QHN]-40 (SEQ ID NO: 101) is likely to assemble into worm-like micelles.

[0140] [Table 9] Another interesting observation is that a simple change between [S]-XX-[QHN]-40 (SEQ ID NO: 100-101) and [S]-XX-[NHQ]-40 (SEQ ID NO: 102-103) resulted in degradation. This result was unexpected because the difference in hydrophobicity between [QHN] and [NHQ] is rather small. However, this result was due to the fact that the two blocks were sufficiently similar to each other. t This small change makes T t This can be understood as narrowing the gap between two blocks of sufficiently similar T t results in a copolypeptide that has only one UCST temperature and behaves as a unimeric unit.

[0141] To gain deeper insight into the morphology of the UCST-UCST constructs, samples were prepared for cryo-TEM. Previous studies have shown that the vitrification process increases the concentration of the solution. In these images, the sample polypeptides are observed to undergo liquid-like phase separation due to the increased concentration. This phase separation makes it impossible to distinguish the nanostructures of the two constructs. However, what is interesting is that there appear to be interconnected structures within the droplet-like liquid (Figure 30). There also appear to be three distinct regions of contrast: the water / buffer surrounding the droplet, the contrast of the droplet itself, and then further contrast of the internal microstructure. This indicates that different RLPs have different contrast during the phase transition, and that RLP-ELP and RLP-RLP, which have different RLPs in their cores, may have measurable differences in core contrast. Both [S]-40-[QHN]-40 (SEQ ID NO: 100) (Figure 30A, C) and [S]-80-[QHN]-40 (SEQ ID NO: 101) (Figure 30B, D) form this microstructure.

[0142] As previously described, temperature-dependent turbidity was determined by UV-visible spectrophotometry. Using this method, we were unable to visualize a clear transition from solubility to aggregates upon cooling. Furthermore, [S]-40-[QHN]-40 (SEQ ID NO: 101) had a distinct UCST aggregation temperature. The concentration dependence of this UCST aggregation was determined for both constructs (Figure 31A). Both constructs had UCST values ​​much higher than predicted by the corona block alone, indicating that fusion to the more hydrophobic RLP conferred the observed UCST behavior only somewhere between the two unimer blocks. Increasing the size of the RLP resulted in a higher UCST, indicating that the corona is influenced by the size of the bound core polypeptide. Compared to the RLP-ELP block copolypeptide, the RLP-RLP block copolypeptide retained much of its concentration dependence, which explains the cryo-TEM results. It is also interesting to note that [S]-80-[QHN]-40 (SEQ ID NO: 101), which is predicted to be the more wormlike of the two, had a higher concentration dependence. This again differs from the previously observed trend for RLP-ELP block copolypeptides.

[0143] The RLP-RLP block copolypeptide retains the inherent pH-responsiveness of the corona unimer. Temperature-dependent DLS measurements at different buffer pH conditions again showed a maximum in the observed UCST aggregation temperature near the isoelectric point of His (Figure 31B). The UCST of both constructs increases approximately linearly from pH 8.4 to pH 6.4, then decreases from pH 6.4 to 3.4. This result makes sense in the context of previous observations. As the pH decreases toward the isoelectric point of His, the corona becomes more hydrophobic, and thus the T t This process is not understood, but is consistent with previous observations. After reaching the isopotential point, T t decreases. This is because the enormous amount of positive charge on the corona chains dramatically increases chain repulsion. It is important to note that in each of these aggregate DLS curves, a stable micellar regime was observed. [S]-40-[QHN]-40 (SEQ ID NO: 100) exhibits a significant decrease in R when the pH is decreased to the isoelectric point.h There appeared to be no significant changes in the size of the [S]-80-[QHN]-40 (SEQ ID NO: 101) as the pH decreased toward the isoelectric point, and then at pH 3.4, it actually fell below its original size measured at pH 7.4. This indicates a morphological change from a worm at neutral pH to a more elongated worm at pH 5.4, and then possibly a spherical shape at pH 3.4.

[0144] The UV-visible measurements did not answer important questions about the temperature-dependent decomposition. Therefore, to get a more accurate picture, the solution was slowly cooled while the R h The temperature-dependent transition from unimolecular to micelle forms was monitored. Two distinct overall behaviors were observed. Upon cooling, [S]-40-[QHN]-40 (SEQ ID NO: 100) transitioned from distinct unimolecular to micelle forms at approximately 55 °C and from distinct micelles to aggregates at 28 °C (Figure 32B). The temperature-dependent unimolecular to micelle transition is known as the critical micellization temperature (CMT). As previously shown, this UCST aggregation temperature depends on the solution concentration. [S]-80-[QHN]-40 (SEQ ID NO: 101) remained micelles at the highest temperature that could be measured instrumentally. Upon cooling, the aggregate size increased slightly until a clear aggregate transition occurred at 18 °C. These two results demonstrate that controlling the core block sequence provides control over the UCST and CMT of the aggregates.

[0145] In addition to these block copolypeptides, the T tWe attempted to understand the differences between the [S]-40 and [Y]-40 blocks. Using a library of repeating IDPs, we progressively fused more hydrophilic blocks to the core sequence [S]-40 by replacing Tyr residues with Val (SEQ ID NO:104). This proved to be the most efficient substitution of an aliphatic residue for an aromatic residue. Furthermore, we found that [S]-40 exceeded the minimum core block size required for assembly. Therefore, we first generated three block copolypeptides with a hydrophilic fraction of approximately 50% by mass. Here, the intended corona chains comprised [Y:V]-40 (i.e., two repeats of SEQ ID NO:30), [Y:3V]-40 (i.e., two repeats of SEQ ID NO:28), and [V]-40 (i.e., two repeats of SEQ ID NO:36), and the core comprised [S]-40 (i.e., two repeats of SEQ ID NO:24).

[0146] UV-visible spectrophotometry and dynamic light scattering (DLS) measurements were highly informative in determining the minimum difference required for self-assembly. These experiments showed that coronas containing [Y:V] and [Y:3V] did not assemble but merely resulted in particle systems that aggregated in a manner approximating liquid-liquid coacervation. Only when Tyr was completely replaced by Val was a self-assembled structure observed. DLS and UV-visible spectrophotometry indicated that upon cooling, an intermediate assembly phase existed in which unimolecular sequences (approximately 10 nm) transitioned to particles of approximately 500 nm before settling into stable 30 nm micelles (Figure 33). Here, unlike the [S]-40 and [QHN]-40,80 constructs, only a single assembly mode was observed with DLS, suggesting that the core collapsed, while the corona chains remained soluble throughout the entire temperature range. These results also indicated that the minimum difference in the core block was 12.5%, indicating a T t It also suggests that the approximate difference is 80-100°C.

[0147] These experiments provide a concept of the core and corona required for assembly. From experiments with UCST and LCST diblocks, we know that relative block size influences micelle assembly. Therefore, to examine assembly size, we varied the corona size and assessed assembly by cryo-TEM. Cryo-TEM images show that the initial construct, [S]-40-[V]-40 (SEQ ID NO: 106), assembled into a mixture of small micelles and large phase-separated domains. These large phase-separated domains increased in size as the corona size decreased (Figure 34). Similarly, increasing the corona size decreased the size of the phase-separated domains, increasing the fraction of the field of view and resulting in an R of approximately 30 nm. h Small spherical particles are formed.

[0148] Finally, combining these two insights, we created a third systematic library in which approximately 10% of the coronal chain was varied with aliphatic amino acids, but with varying hydrophobicity as predicted by the other hydrophobicity scales. Ala, Ise, and Val all exhibited similar effects on the UCST phase separation behavior of polypeptides, with the only difference between each of these amino acids being the extra hydrocarbon on the side group. Therefore, we created proteins with [S]-40-[I]-40 (SEQ ID NO: 109) and [S]-40-[A]-40 (SEQ ID NO: 108) in addition to [S]-40-[V]-40 (SEQ ID NO: 106). These cryo-TEM images suggest that decreasing the hydrophobicity of the chains eliminates the presence of phase-separated domains and shifts the aggregate phase to a mixture of wormlike and spherical micelles, including the presence of some vesicles. Increasing the hydrophobicity of the corona increases the size and hydrophobicity of the phase-separated domains, which become associated with the hydrocarbon grid.

[0149] By employing the core UCST block, we were highly successful overall in generating predictable self-assembling block copolypeptides. The mutational pathways pursued were governed by simple diblock assembly principles from polymer physics and generally yielded effects predicted by theory. Unlike previous protein assembly systems, whose behavior was more challenging than predicted a priori, the self-assembly of RLP-ELP block copolypeptides can be understood in terms of hydrophilic mass fractions, polypeptide-polypeptide, and polypeptide-solvent interactions. This finding is significant because it provides a route for the de novo design of desired nanoscale morphologies from first principles to a wide variety of shapes and sizes.

[0150] Using these block copolypeptides as assembly scaffolds, the results clearly demonstrate that RLPXX-ELP80 block copolypeptides are a robust platform for multivalent display of Fn3 domains via self-assembly. By adjusting the core block ratio and molecular weight, the morphology of the parent micelles can be tuned from spherical to worm-like. Decreasing the hydrophilic mass fraction from approximately 0.7 to approximately 0.46 to approximately 0.30 changes the morphology from unimolecular to spherical micelles to worm-like micelles, respectively. Importantly, genetic fusion of the αvβ3 integrin-targeting Fn3 domain to the hydrophilic C-terminus of the RLPXX-ELP block copolypeptide does not prevent self-assembly and allows high-density display of the Fn3 domain on the corona of the micelles. However, Fn3 display does affect morphology, as the parent RLPXX-ELP80 micelles, which reside at the phase boundary between spherical and worm-like micelles, are converted to worm-like micelles upon displaying the Fn3 domain on the corona of the block copolypeptide.

[0151] Cellular uptake studies of Fn3-presenting RLP-ELP block copolypeptides with αvβ3-overexpressing cell lines yielded four striking results: first, compared with parent ligand-negative micelles, in the best case, worm-like micelles had three-fold increased cellular uptake in 2 h, demonstrating that multivalency can significantly enhance the targeting potency of ligands solely through the avidity effect. Second, RLPs that do not self-assemble into micelles and therefore display only a single copy of the Fn3 domain targeting αvβ3 integrin were not able to self-assemble into micelles. n Compared to RLP80-ELP80-Fn3 fusions, multivalent spherical and worm-shaped micelles were found to have higher avidity and higher cellular uptake. This demonstrates the importance of multivalency, which amplifies ligand avidity by displaying multiple copies on nanoscale scaffolds. Third, we observed dramatic differences in cellular uptake as functional micellar morphologies, with Fn3-decorated worm-shaped micelles exhibiting a five-fold increase in cellular uptake compared to spherical micelles. Fourth, we believe that morphology is more important than size, as worm-shaped micelles with the same hydrophilic mass fraction as RLP80-ELP80-Fn3 (SEQ ID NO: 97) but smaller size exhibited higher levels of cellular uptake than comparable-sized spherical micelles (RLP40-ELP80-Fn3) (SEQ ID NO: 96). Similarly, spherical particles of similar size to RLP80-ELP80-Fn3 (SEQ ID NO: 97) worm-shaped micelles exhibited very low levels of uptake. These data indicate that the elongated shape and flexibility of worm-like micelles increased the number of accessible Fn3 ligands available for receptor binding. Fifth, the avidity and cellular uptake of the best-performing worm-like micelles were greater than that of therapeutically relevant antibodies targeting the same receptor.

[0152] Compared to other ELP-based nanostructures, this class of self-assembling RLP-ELP block copolypeptides offers an extremely robust and versatile system for the molecular design and recombinant synthesis of micelles for drug and imaging agent delivery for the following reasons: First, unlike ELP block copolypeptides, RLP-ELP block copolypeptides follow the canonical rules of polymer self-assembly via genetic coding sequences, which facilitates de novo programming of their morphology for specific applications. Second, these micelles have significantly higher thermodynamic stability than ELP micelles, with CMCs in the 0.1 μM range or less, compared to the 5-10 μM CMC of ELP micelles. Third, these micelles allow the presentation of the Fn3 domain on the micelle corona, making them an attractive choice as targeting ligands because the Fn3 scaffold is a highly mutable targeting scaffold, allowing for the discovery of variants through library screening approaches against diverse targets. Fourth, it is noteworthy that these targeted micelles can be loaded with drugs simply by conjugation of small molecule drugs into the core-forming hydrophobic domain, in a manner similar to previous ELP micelles. Finally, their production, and therefore clinical translation, impacts the bacterial fermentation and downstream purification capabilities of the biopharmaceutical industry.

[0153] Example 5 We decided to thoroughly investigate the effects of pAzF introduction and nanoparticle cross-linking on nanoparticle self-assembly. To this end, we began by characterizing five different ELP / RLP diblock architectures alone, without C-terminal functionalization. After expressing and purifying the diblock constructs using ITC, the pAzF-containing constructs were cross-linked in solution by exposure to UV irradiation and characterized using dynamic light scattering (DLS). The measured hydrodynamic radius (R h ) showed that both the introduction of unnatural amino acids into the polypeptide sequence and, in particular, the cross-linking process itself, affected the general size of the particles (Table 10). Overall, both processes appeared to increase the measured radius, with this effect being more pronounced for worm-forming constructs.

[0154] [Table 10]

[0155] Apart from changes in nanoparticle morphology, we were particularly interested in the effect of pAzF crosslinking on their stability. To assess whether the crosslinking process actually resulted in a significant increase in stability, the particles were exposed to guanidine hydrochloride (GuHCl). GuHCl is a well-known denaturant that disrupts any inter- and intramolecular electrostatic forces and completely disassembles the quaternary, tertiary, and secondary structure of most known proteins. However, covalent bonds, such as those formed by pAzF crosslinking, remained unaffected by GuHCl, and therefore, the addition of this denaturant was expected to provide insight into the stability of the crosslinked nanoparticles. Further DLS experiments demonstrated that crosslinking did indeed result in the desired increase in stability. All crosslinked samples in GuHCl exhibited R values ​​in the same general range as those previously measured in phosphate-buffered saline (PBS). h On the other hand, all natural samples completed unimerization upon exposure to GuHCl. The R of cross-linked particles in GuHCl h The DLS data further indicate swelling behavior in the presence of denaturants, as values ​​were generally larger than in PBS, likely due to the RLP core, which is assumed to completely collapse in PBS, attempting to reach an elongated random coil conformation in the presence of GuHCl.

[0156] Finally, the data set also showed that the UAA2-40 and UAA5-40 constructs were identical in terms of both particle morphology and stability. Two pAzF residues per polypeptide chain appeared to be sufficient to achieve stable crosslinking. To determine the minimum pAzF density required for stable crosslinking, the UAA2 / 5-40 construct was mixed with a pAzF-free DB-40 diblock and crosslinked at 50, 60, 70, 80, and 90 percent DB-40 fractions. Subsequent DLS characterization in 7.2 M GuHCl then indicated a cutoff of approximately one pAzF residue per ELP / RLP chain, which is, in principle, a very intuitive result (Figure 36). While the average DLS readings appeared to indicate a fairly sharp transition, closer examination showed that this was not actually the case. A secondary population corresponding to a unimer fraction was observed that continuously decreased in size with increasing pAzF density, ranging from one to two pAzF sites per diblock.

[0157] Because DLS only provides insight into the general size of the nanoparticles and does not reveal any potential changes in morphology from one sample to another, we decided to perform cryo-transmission electron microscopy (cryo-TEM) imaging to image the particles in a near-native state. For the sphere-forming diblock architecture (UAA5 variant), cryo-TEM supports the light scattering data, showing that spherical particles slightly enlarge upon exposure to GuHCl in the crosslinked regime, but completely disintegrate without prior crosslinking (Figure 37). Furthermore, the images confirm our previous observation that the crosslinking process itself already results in a significant increase in particle size. Image analysis then revealed that the particle radius was significantly below the DLS value (Figure 37C). This can be explained by our previous observation that only the collapsed micelle core possesses electron density high enough to be imaged by TEM. Subtracting the measured core radius from the corresponding Rh value from DLS also reveals that the change in particle size upon GuHCl exposure is indeed due to the expansion of the RLP core, not the ELP corona.

[0158] Cryo-TEM images of the worm-forming constructs revealed a somewhat unexpected picture, with worms measuring several micrometers in length after crosslinking (Figure 37C). The particles in images taken under native conditions were not as elongated as those in the crosslinked state, suggesting an artifact of particle rearrangement on the grid surface during deposition. This data indicates that pAzF crosslinking can occur on a timescale larger than that of polypeptide rearrangements, allowing particles to adopt new morphologies in response to crosslinking. In both cases, these elongated structures were robust to denaturing conditions relative to their spherical counterparts.

[0159] Finally, we aimed to determine the critical assembly concentration (CAC) of each construct. h CAC values ​​were measured by DLS across a dilution series from the mid-micromolar to low-nanomolar range. The resulting hydrodynamic radii indicated that the sphere-forming constructs were generally more stable than their worm-forming analogs, with the DB-40 and DB-80 constructs degrading at low-micromolar and mid-nanomolar concentrations, respectively (Figure 38). Curiously, simply introducing cross-linking sites appears to dramatically reduce CAC. Overall, the worm-forming constructs had lower CACs than their globular analogs, and pAzF-containing constructs were similar compared to analogous non-pAzF-containing polypeptides. To generate particles capable of targeting specific cell receptors, protein ligands were genetically fused to the outside of crosslinkable particles. The nanoparticle-ligand fusions exhibited significantly stronger expression than other non-native expression systems (Figure 39A, B). All but one culture produced liquid cultures exceeding 10 milligrams per liter.

[0160] The first step in the characterization process was to generate crosslinked particles for the functionalized diblock constructs and analyze whether ligand attachment caused significant changes in particle size. Subsequent DLS analysis showed that functionalization did not have any substantial effect on most of the nanoparticle architectures (Table 11). The two exceptions were the constructs carrying the AHNP and TRAIL peptide ligands, which exhibited significantly increased and decreased hydrodynamic radii, respectively. The most plausible explanation is that this was caused by the observed decrease in solubility for both of these constructs, which could have significantly altered their actual concentrations in solution. Whatever the reason, the crosslinking process was not affected, as the particles remained stable after GuHCl exposure.

[0161] [Table 11] A series of cellular experiments were performed to determine the effect of crosslinking on ligand uptake. More specifically, experiments were performed on four different cell lines, depending on the type of ligand: the colon cancer cell line Colo205 was used for apoptosis-inducing DR5-targeting ligands (Tn3 and TRAIL peptides), the breast cancer cell line SK-BR-3 was selected to determine the potency of ErbB2-binding AHNP ligands, and two different variants of the leukemia cell line K562 (native and transfected with the gene for αvβ3-integrin; see Dzuricky et al.) were used to characterize integrin-targeting constructs. Leukemia cell lines were also used to test Polyvia-MPI, which has been reported to be cytotoxic to K562 cells.

[0162] The potency of the three cytotoxic ligands, Tn3, TRAIL peptide, and Polyvia-MPI, was evaluated by performing cell viability assays on each cell line at different concentrations. The data subsequently collected showed that only exposure to Tn3-functionalized nanoparticles resulted in any cell death (Figure 40). For the other two constructs, cells showed complete survival within the investigated concentration range. With an EC50 value of 470 pM, the Tn3 sample still induced cell death at a concentration significantly below the CAC of the UAA5-40 construct.

[0163] To investigate the possibility of nonspecific uptake, non-functionalized constructs of all six ligands were also tested on SK-BR-3 cells. Confocal images obtained after 2 hours of co-incubation with crosslinked AlexaFluor-488-tagged nanoparticles at a concentration of 7 μM are shown in Figure 41. The images clearly demonstrate that AHNP functionalization did not result in increased cellular uptake compared to the other ligands, suggesting that the ligands respond differently to multivalent presentation and, therefore, that engineering multivalent presentation is important for engineered function.

[0164] Finally, we performed cellular uptake experiments in two other cell lines. Here, we tested three different ligands: the integrin-targeting ligands Fn3 and GRGDSPAS, and PolyVia-MPI. Confocal images taken after 2 hours of co-incubation at 7 μM showed that cross-linked PolyVia-MPI particles were indeed the most efficiently internalized of all three functionalized constructs (Figure 42A). Furthermore, both integrin-targeting ligands showed increased uptake levels of the avβ3-presenting K562 variant, whereas no significant increase was observed in native K562 cells compared to the non-functionalized control. Faced with these positive results in the CAC regime described above, we also tested all three ligands at a concentration of 70 nM—this time, only in αvβ3-positive cell lines. While this concentration may still exceed the CAC of the constructs, the detection limit of the cellular uptake assay (approximately 10 nM) prevented further dilutions. The resulting confocal images then showed that both GRGDSPAS and Fn3-loaded nanoparticles were still taken up in significant amounts, but no increase in cellular uptake was observed for Polyvia-MPI (FIG. 42B).

[0165] Before testing the effect of nanoscale shape on the wormlike UAA4-80-K8D4-ligand constructs, we characterized their self-assembly: while the addition of these three ligands had no significant effect on the DLS readings of spherical nanoparticles (Table 10), a systematic decrease of approximately 20 nm in the hydrodynamic radius was observed for the wormlike constructs (Figure 44A). Given these results and the fact that Rh values ​​do not very accurately represent particles with elongated morphologies, we next turned to cryo-TEM to better understand what might have caused this systematic change. The resulting images clearly showed that the addition of the K8D4-linker and three different ligands to the corona of the ELP / RLP diblock caused the protein to adopt a spherical rather than wormlike morphology (Figure 44B-D). The radius of the particles in the cryo-TEM images was determined to be 20–40 nm, in accordance with the DLS readings when including the solvated, and therefore invisible, ELP corona (Figure 44F). Although such spherical micelles were already observed in some of the cryo-TEM images of undecorated UAA4-80 constructs, they were only minor by-products (Figure 4E). Functionalization of these constructs appears to have strongly shifted this equilibrium toward the low aspect ratio fraction.

[0166] Because this change in particle morphology was as pronounced for the short GRGDSPAS ligand as it was for the larger Fn3 and Tn3 protein scaffolds, it seems likely that the introduction of the K8D4 linker was the primary cause of this effect. Due to the charge and hydrophilicity of this linker, it seems reasonable that the attachment of such peptides to the corona generally lowers the aspect ratio. However, DLS characterization of the linker-free UAA4-80 construct showed an unchanged hydrodynamic radius (Figure 45A). Subsequent TEM images also confirmed that the construct without the K8D4 linker still formed spherical particles rather than worm-like particles (Figure 45B-E). However, this does not mean that the addition of the linker did not affect particle morphology: in fact, UAA4-80-K8D4 nanoparticles showed an even greater size reduction than the ligand-loaded constructs (Figure 45F). This suggests that determining self-assembly in the presence of corona proteins and peptide sequences is difficult.

[0167] Although removal of the K8D4 linker did not ultimately promote worm-like morphology, the resulting particles were also more worm-like than linker-bearing particles. Therefore, the first experiment to evaluate the benefits of the multivalency of crosslinked nanoparticles was to determine whether there was a difference in binding affinity between linker-free and linker-bearing constructs. To this end, cell viability experiments were performed using crosslinked versions of the Tn3-functionalized constructs. The resulting data showed that for both the UAA5-40 and UAA4-80 constructs, the K8D4-containing constructs were significantly more potent than their linker-free analogs (Figure 46). Because the Tn3 ligand is a 104-aa protein scaffold and therefore generally not expected to be at risk for hydrophobic burial, it seems highly unexpected that removal of the linker had such a dramatic effect on particle potency. One alternative hypothesis is that this highly charged linker generally aids in cellular targeting through electrostatic interactions with the cell membrane. It seems plausible that the K8D4 linker, which has a net charge of +4, may facilitate cellular uptake due to its negative charge on cell membranes, especially in tumor tissues.

[0168] The cell survival plots in Figure 46 also show that particles with UAA5-40 bases were generally slightly more potent than particles constructed from UAA4-80 diblocks. This observation was also somewhat counterintuitive, as larger spheres with lower curvature would generally be expected to have a higher contact area with the cell membrane and therefore bind to displayed receptors more efficiently. However, the TEM images in Figure 44 showed that the particles with UAA4-80 bases were not perfect spheres. This, in turn, indicated that the self-assembly and / or cross-linking of these constructs may have been more chaotic than UAA5-40 particles, thus potentially impairing ligand exposure.

[0169] Finally, the cell viability curves for crosslinked UAA5-40-K8D4-Tn3 particles in Figure 46 matched almost perfectly with those from previous ligand screening experiments (Figure 43). While the reproducibility of the data was gratifying, it also meant that the slight increase in cell viability observed for concentrations around 1 μM was indeed true. For all concentrations in this range, cell viability remained below 30%, a rather puzzling observation. Particularly perplexing was the fact that further increases in concentration to 7 μM returned cell viability to 0%. Consequently, this effect could not be explained by a high-concentration phenomenon such as nanoparticle clustering, but rather was caused by something that only appeared at concentrations around 1 μM.

[0170] Similar cell viability assays were subsequently performed on the corresponding native constructs to quantify the benefits of multivalency upon crosslinking. These experiments yielded some promising results. For both diblock architectures, crosslinking significantly increased the potency of the respective nanoformulations (Figure 46A). For the functionalized UAA5-40 construct, crosslinking reduced the EC50 values ​​by more than three orders of magnitude. Furthermore, comparison of these cell viability results with the CACs previously recorded for the native UAA5 / 4-40 / 80 and DB-40 / 80 constructs demonstrated a strong correlation: the EC50 values ​​of the native DR5-targeting constructs were in near perfect agreement with the CACs of the DB-40 and DB-80 constructs (Figure 46B). While it remains largely unclear why the CACs determined for the UAA5 / 4-40 / 80 diblocks differ so significantly from their non-pAzF-containing analogs, these observations strongly indicated that the differences were not in fact true. EC 50 The near-perfect correlation between the values ​​and the CAC of the DB-40 / 80 constructs seemed highly unlikely to be coincidental and not due to CAC-dependent particle degradation. Thus, this result indicates that CAC is a limiting factor in the efficacy of multivalent beneficial ligands in self-assembled nanoparticles and that chemical cross-linking is a powerful tool to overcome this problem.

[0171] In additional follow-up experiments, we then investigated how different ligand densities of crosslinked nanoparticles affected overall potency. To this end, crosslinked particles consisting of both the nonfunctionalized UAA5-40 diblock and the UAA5-40-K8D4-Tn3 construct were prepared at molar ratios of 1:3, 1:1, and 3:1. Subsequent cell viability assays using these constructs showed that reducing nanoparticle functionalization by 50% resulted in only a slight change in potency (Figure 47). Only when the functionalized ELP / RLP diblock in the nanoparticles was further reduced to 25% did the measured EC50 value significantly increase into the high nanomolar range. The nonlinearity of the observed trend further suggests that the two constructs readily mix and that the change in potency is indeed the result of a decrease in ligand density on the nanoparticle surface. These observations are even more encouraging when we consider that the UAA5-40-K8D4-Tn3 construct was not completely pure to begin with, as it contained a significant amount of cleavage products (Figure 39A). At least half of the Tn3 ligands on fully functionalized nanoparticles could theoretically be removed without compromising the efficacy of the formulation, thus representing a good starting point for further engineering of this system, for example, towards bispecific nanoparticles.

[0172] We were interested in assessing larger cell populations by flow cytometry. We performed various experiments with various protein-based ligands of various sizes at various concentrations in various crosslinking states (Figures 48-50). Several conclusions can be drawn from this work. First, in all cases, we observe an increased effect of multivalent presentation with proteins and peptides. This is unexpected and nontrivial, as proteins and peptides have different mechanisms of binding to the cell surface, differ in nominal size, and can be internalized by various routes. It is clear that this multivalent effect of induced cellular uptake is statistically motivated, as even nonspecifically targeted crosslinked particles can exhibit high levels of uptake when localized charges are present on the coronal surface (Figure 49). However, micelle stability dramatically impacts this cellular uptake, as reducing the concentration of noncrosslinked particles essentially eliminates this nonspecific uptake (Figure 50). The efficacy of this result appears to be somewhat ligand- and concentration-dependent, consistent with previous examples, but a similar effect of particle shape on uptake is also observed (Figure 48).

[0173] While we were interested in the downstream effects of treatment with crosslinked nanoparticles, we also wanted to know how chemical crosslinking affected binding to the cell membrane receptor itself. To this end, we assessed the binding affinity of the crosslinked and native diblock architectures using surface plasmon resonance (SPR).

[0174] To characterize the integrin-targeting constructs, K of UAA5-40-based constructs D We began by determining K values, which yielded unexpectedly tight binding affinities of 3.3 nM and 20 nM for the Fn3 and GRGDSPAS ligands, respectively (Figure 51A). Specifically, for the peptide ligands, the K values ​​recorded for the crosslinked nanoparticles were D The values ​​are also significantly lower than those for similar non-pAzF-containing constructs. Inspection of the SPR sensograms reveals that the K D The main reason for the increase is k offThe association rate (k on ) are very different outcomes, we explain the mechanism of this effect. For their uncrosslinked analogs, no binding was observed for the GRGDSPAS construct, while some binding (to a lesser extent for the crosslinked sample) was measured for the Fn3 variants (Figure 51B). Based on the results of the cellular uptake studies, it was expected that the native Fn3 construct might exhibit some binding due to its increased unimeric binding affinity compared to the GRGDSPAS variants. At concentrations above CAC, crosslinking did not significantly affect binding affinity (Figure 51C).

[0175] For integrin-targeting constructs with the larger UAA4-80 construct, the SPR results were unexpected: SPR data for cross-linked GRGDSPAS-functionalized particles showed very strong binding at a concentration of 190 nM, but the signal dropped off rapidly upon further dilution (Figure 52A). For the cross-linked Fn3 construct, on the other hand, the sensograms appeared somewhat resolved from concentration (Figure 52B). At 68 nM, SPR data showed strong binding, but no binding was detected both above and below that value. Consequently, the K for GRGDSPAS particles was calculated at 85 nM, in the mid-nanomolar range. D Only the CAC of the ELP / RLP constructs could be determined (Figure 52C). Neither of the two crosslinked particles showed detectable binding at dilutions below the CAC, so the benefit of multivalency upon crosslinking could not be demonstrated for either of these integrin-targeting constructs. This is likely due to the relatively low binding affinity of this biblock architecture to nanoparticles combined with the low CAC of these ELP / RLP constructs.

[0176] Initial characterization of crosslinked Tn3 samples using the UAA5-40 base in the sub-CAC regime demonstrated deep K values ​​in the picomolar range. Dvalues ​​were obtained (Figure 53A). This extremely good binding constant may be due to a low k rate, which may be below the detection limit of the SPR instrument. However, in contrast to the integrin-targeted UAA5-40 particles, very strong binding was observed for the native Tn3 construct within the same concentration range (Figure 53B). At 250 nM, the calculated K D The value increased only 12-fold compared to the cross-linked sample. This suggested that cross-linking still improved DR5 binding, but only to a very limited extent. This was not entirely unexpected, since it was already known in principle that apoptosis induction via DR5 binding requires downstream trimerization of the ligand-bound DR5 receptor in the plasma membrane. Therefore, we expected that the reported requirement for multivalency of Tn3 action was due, at least in part, to this mechanistic effect, rather than to DR5 binding itself.

[0177] Example 6 An engineered domain from Staphylococcus aureus (SpA) protein A (termed the Z domain, or ZD) was genetically fused to the exterior of an RLP-ELP block copolymer, expressed in E. coli, and purified as previously described. To demonstrate the utility of capturing antibodies using the multivalent effect rather than the traditional control ELP approach, capture and elution experiments were performed in a microfuge format using three different antibodies (mAbs). First, the mAb was "captured." This involves incubating the RLP-ELP-ZD diblock in the presence of the antibody for approximately 1 minute at room temperature. Next, phase separation was triggered by heating to 37°C or adding NaCl to the solution. Large aggregates of RLP-ELP-ZD-mAb either settled over time or could be quickly pelleted by centrifugation. The sample was then resuspended in a low pH buffer to dissociate the mAb from the RLP-ELP-ZD and release it into the elution fraction (elution SN). Therefore, we expect that the heavy and light chains of the antibody in the elution SN and capture SN will be insufficient. As shown in the control ELP case, the effectiveness of this process varied among the three different model antibody compounds, meaning that there was variation in the levels of capture and elution among the three mAbs (Figure 54). With the RLP-ELP-ZD construct, the capture SN consistently contained very little mAb, suggesting that the increased binding affinity of the ZD for mAb and the high-efficiency capture through the overall size of the self-assembled particles reduced variability in the process and allowed for efficient separation of contaminants (other bands seen in lanes 1, 3, and 5) from the mAb product.

[0178] Example 7 Dynamic light scattering was performed on crosslinked protein nanoparticles. At 0.7 μM in 7.2 M GuHCl, noncovalently crosslinked polypeptides disassemble into small unimolecular structures (radius approximately 7–10 nM) that do not self-assemble. However, these crosslinked particles remain assembled and, in fact, become slightly larger due to chain expansion of the core and corona in this new buffer. These novel scaffolds support various targeting domains and assemble into similarly sized nanoparticles with hydrodynamic radii of 32–52 nM.

[0179] [Table 12] Another aspect of the present invention may be as follows. [1] A composition comprising protein nanoparticles containing a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide. [2] The composition described in [1], wherein the fusion protein comprises multiple unstructured polypeptides. [3] The composition described in [1], wherein the fusion protein comprises multiple targeting polypeptides. [4] The composition described in [1], wherein the unstructured polypeptide comprises a diblock peptide. [5] The composition described in [1], wherein the unstructured polypeptide comprises a diblock of a core polypeptide and a corona polypeptide. [6] The unstructured polypeptide is a core n -corona m The composition according to [1] above, wherein n is a repeating number of 20 to 200 and m is a repeating number of 40 to 200. [7] The composition of [1], wherein the core polypeptide comprises the sequence QYPSDGRG (SEQ ID NO: 1), GRGDQPYQ (SEQ ID NO: 2), GRGDSPYQ (SEQ ID NO: 3), GRGDSPYS (SEQ ID NO: 4), GRGDQPYS (SEQ ID NO: 5), GRGDSP[3Y:V]S (SEQ ID NO: 6), GRGDSP(Y:V]S (SEQ ID NO: 7), or a combination thereof. [8] The composition described in [1], wherein the corona polypeptide comprises the sequence VPG[A:G]G (SEQ ID NO: 8), VPGSG (SEQ ID NO: 9), VPGVG (SEQ ID NO: 10), VPQQG (SEQ ID NO: 11), GRGDSPAS (SEQ ID NO: 12), GRGDSPIS (SEQ ID NO: 13), GRGDSPVS (SEQ ID NO: 14), GRGDQPHN (SEQ ID NO: 15), GRGDNPHQ (SEQ ID NO: 16), GRGDSPV (SEQ ID NO: 17), or a combination thereof. [9] The core polypeptide has the sequence (RLP) n The composition according to [1] above, which contains (SEQ ID NO: 1), wherein n is a repeating number of 20 to 200.

[10] The composition described in [1], wherein the corona polypeptide comprises the sequence (ELP)m (sequence number 8), where m is the number of repeats of 40 to 200.

[11] The diblock is RLP40-ELP40 (SEQ ID NO: 83), RLP40-ELP80 (SEQ ID NO: 84), RLP40-ELP160 (SEQ ID NO: 82), RLP60-ELP80 (SEQ ID NO: 85), RLP80-ELP80 (SEQ ID NO: 87), RLP80-ELP160 (SEQ ID NO: 86), or RLP100-ELP80 (SEQ ID NO: 88) The composition according to [1] above, comprising:

[12] The composition described in [1], wherein the targeting polypeptide comprises a polypeptide of 2 kDa to 100 kDa.

[13] The composition of [1], wherein the targeting polypeptide comprises a type III domain derived from human fibronectin (Fn3) (SEQ ID NO: 60), an aFn3 domain derived from human tenascin C (Tn3) (SEQ ID NO: 62), or a Z domain of staphylococcal protein A (SEQ ID NO: 64).

[14] The composition described in [1], wherein the targeting polypeptide comprises a type III domain derived from human fibronectin (Fn3) (SEQ ID NO: 60).

[15] The composition described in [1], wherein the targeting polypeptide comprises an Fn3 domain derived from human tenascin-C (Tn3) (SEQ ID NO: 62).

[16] The composition described in [1], wherein the targeting polypeptide comprises the Z domain of Staphylococcus aureus protein A having an array including (SEQ ID NO: 64).

[17] The composition described in [1], wherein the core polypeptide is cross-linked.

[18] A protein nanoparticle comprising a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide.

[19] The protein nanoparticle described in

[18] , wherein the fusion protein comprises multiple unstructured polypeptides.

[20] The protein nanoparticle described in

[18] , wherein the fusion protein comprises multiple binding polypeptides.

[21] The protein nanoparticle described in

[18] , wherein the unstructured polypeptide comprises a diblock peptide.

[22] The protein nanoparticle described in

[18] , wherein the unstructured polypeptide comprises a diblock of a core polypeptide and a corona polypeptide.

[23] The unstructured polypeptide is a core n -corona m wherein n is the number of repetitions of 20 to 200 and m is the number of repetitions of 40 to 200.

[24] The protein nanoparticle of

[18] , wherein the core polypeptide comprises the sequence QYPSDGRG (SEQ ID NO: 1), GRGDQPYQ (SEQ ID NO: 2), GRGDSPYQ (SEQ ID NO: 3), GRGDSPYS (SEQ ID NO: 4), GRGDQPYS (SEQ ID NO: 5), GRGDSP[3Y:V]S (SEQ ID NO: 6), GRGDSP(Y:V]S (SEQ ID NO: 7), or a combination thereof.

[25] The protein nanoparticle described in

[18] , wherein the repeating core polypeptide sequence is interspersed with at least 1 to 10 non-classical amino acids selected from azidophenylalanine, acetylphenylalanine, propargyloxyphenylalanine, acetylphenylalanine, or azidohomoalanine.

[26] The protein nanoparticle described in

[18] , wherein the corona polypeptide comprises the sequence VPG[A:G]G (sequence number 8), VPGSG (sequence number 9), VPGVG (sequence number 10), VPQQG (sequence number 11), GRGDSPAS (sequence number 12), GRGDSPIS (sequence number 13), GRGDSPVS (sequence number 14), GRGDQPHN (sequence number 15), GRGDNPHQ (sequence number 16), GRGDSPV (sequence number 17), or a combination thereof.

[27] The core polypeptide has the sequence (RLP) n The protein nanoparticle according to

[18] above, comprising (SEQ ID NO: 1), wherein n is a repeat number of 20 to 200.

[28] The protein nanoparticle described in

[18] , wherein the corona polypeptide comprises the sequence (ELP)m (sequence number 8), where m is the number of repetitions of 40 to 200.

[29] The diblock is RLP40-ELP40 (SEQ ID NO: 83), RLP40-ELP80 (SEQ ID NO: 84), RLP40-ELP160 (SEQ ID NO: 82), RLP60-ELP80 (SEQ ID NO: 85), RLP80-ELP80 (SEQ ID NO: 87), RLP80-ELP160 (SEQ ID NO: 86), or RLP100-ELP80 (SEQ ID NO: 88) The protein nanoparticle according to

[18] , comprising:

[30] The protein nanoparticle described in

[18] , wherein the targeting polypeptide comprises a polypeptide of 2 kDa to 100 kDa.

[31] The protein nanoparticle of

[18] , wherein the binding polypeptide comprises a type III domain derived from human fibronectin (Fn3) (SEQ ID NO: 60), an Fn3 domain derived from human tenascin C (Tn3) (SEQ ID NO: 62), or the Z domain of Staphylococcus aureus protein A (SEQ ID NO: 64).

[32] The protein nanoparticle described in

[18] , wherein the binding polypeptide comprises a type III domain derived from human fibronectin (Fn3) (sequence number 60).

[33] The protein nanoparticle described in

[18] , wherein the binding polypeptide comprises an Fn3 domain derived from human tenascin-C (Tn3) (sequence number 62).

[34] The protein nanoparticle described in

[18] , wherein the binding polypeptide comprises the Z domain of Staphylococcus aureus protein A having an array including (SEQ ID NO: 64).

[35] The protein nanoparticle described in

[18] , wherein the binding polypeptide comprises ErbB2 receptor-associated protein (ANHP) (sequence number 74).

[36] The protein nanoparticle described in

[18] , wherein the binding polypeptide comprises a cell-binding peptide (GRGDSPAS) (sequence number 76).

[37] The protein nanoparticle described in

[18] , wherein the binding polypeptide comprises adeno-associated virus (AAV) binding protein (PKD2) (sequence number 112).

[38] The protein nanoparticle described in

[18] , wherein the binding polypeptide comprises adenovirus (AdV) binding protein (CAR) (sequence number 114).

[39] The protein nanoparticle described in

[18] , wherein the binding polypeptide comprises lentivirus (LV) binding protein (CR2) (SEQ ID NO: 116) or (CR3) (SEQ ID NO: 118).

[40] The protein nanoparticle described in

[18] , wherein the binding polypeptide comprises albumin binding protein (ABP) (sequence number 120).

[41] The protein nanoparticle described in any one of

[22] to

[40] above, wherein the core is covalently crosslinked using a linker compatible with photo or other click chemistry.

[42] The protein nanoparticle of any one of

[22] to

[41] above, wherein the core polypeptide is crosslinked.

[43] The protein nanoparticle according to

[18] , wherein the nanoparticle encapsulates one or more types of low molecular weight drugs inside.

[44] The protein nanoparticle described in

[18] , wherein the fusion protein further contains a therapeutic protein.

[45] The protein nanoparticle described in

[18] , wherein the composition is a therapeutic agent, a targeted delivery agent, a separation agent, or a purification agent.

[46] A therapeutic agent comprising the protein nanoparticle described in

[18] .

[47] A method for targeting a therapeutic agent to a cell, comprising administering the protein nanoparticle described in

[18] .

[48] ​​A method for delivering a therapeutic agent to a cell, comprising administering the protein nanoparticle described in

[18] .

[49] A means for targeting a therapeutic agent to a cell, comprising administering the protein nanoparticle described in

[18] .

[50] A means for delivering a therapeutic agent to a cell, comprising administering the protein nanoparticle described in

[18] .

[51] A method for identifying a biomolecule, wherein the protein nanoparticles described in

[18] are added to a solution containing the biomolecule, and the protein nanoparticles specifically bind to the biomolecule.

[52] A method for purifying a biomolecule, comprising isolating the biomolecule from a culture medium or complex matrix using the protein nanoparticle described in

[18] that binds to the biomolecule. 53. The method of claim 52, further comprising triggering phase separation of the binding polypeptide to isolate the biomolecule from contaminants, wherein the trigger is selected from adjusting temperature, salinity, light, pH, pressure, the concentration of the binding polypeptide or the concentration of the biomolecule, application of electromagnetic or acoustic waves, or addition of one or more excipients, including one or more of a cofactor, a surfactant, a crowding agent, a reducing agent, an oxidizing agent, a denaturant, or an enzyme.

[54] The method of

[52] , further comprising using centrifugation to separate high density phase-separated proteins bound to the biomolecules from contaminating biomolecules.

[55] The method of

[52] , further comprising using centrifugation to separate phase-separated proteins bound to the biomolecule from contaminating biomolecules.

[56] The method of

[52] , further comprising isolating the biomolecule from contaminant species using the size of the phase separation droplets, wherein the size of the binding polypeptide bound to the biomolecule is at least 20 nm and not more than 100 μm in diameter.

[57] The method of

[52] , comprising isolating the biomolecule-binding polypeptide complex from contaminant species based on size using flow filtration, membrane chromatography, analytical ultracentrifugation, high performance liquid chromatography, membrane chromatography, normal flow filtration, sonic separation, centrifugation, counterflow centrifugation, and high speed protein liquid chromatography.

[58] The method according to

[52] , wherein the biological molecule comprises at least one of lipids, cells, proteins, nucleic acids, carbohydrates, and virus particles, the nucleic acid is single-stranded or double-stranded DNA or RNA, the virus particle is an adenovirus particle, an adeno-associated virus particle, a lentivirus particle, a retrovirus particle, a poxvirus particle, a measles virus particle, or a herpesvirus particle, and the protein is human albumin, a monoclonal IgG antibody, or an Fc fusion antibody.

Claims

1. a fusion protein comprising at least one binding polypeptide and at least one unstructured polypeptide, the unstructured polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 81-84, 86-94, and 110; the binding polypeptide is Staphylococcal protein A Z domain (SEQ ID NO: 64); Adeno-associated virus (AAV) binding protein (PKD2) (SEQ ID NO: 112); Adenovirus (AdV) binding protein (CAR) (SEQ ID NO: 114); Lentivirus (LV) binding protein (CR2) (SEQ ID NO: 116) or (CR3) (SEQ ID NO: 118); or Protein nanoparticles comprising albumin binding protein (ABP) (SEQ ID NO: 120).

2. The protein nanoparticle of claim 1, wherein the fusion protein comprises multiple unstructured polypeptides or multiple binding polypeptides.

3. A protein nanoparticle described in claim 1 or 2, wherein the unstructured polypeptide is crosslinked.

4. The protein nanoparticle of claim 1, wherein the nanoparticle encapsulates one or more small molecule drugs therein, or the fusion protein further comprises a therapeutic protein.

5. A composition comprising the protein nanoparticle of claim 1, which may be a therapeutic agent, a targeted delivery agent, a separation agent, or a purification agent.

6. 5. The protein nanoparticle of claim 4 for use in a method for targeting or delivering a therapeutic protein or one or more small molecule drugs to cells in vivo.

7. A method for identifying a biomolecule, wherein the protein nanoparticles described in claim 1 are added to a solution containing the biomolecule, and the protein nanoparticles specifically bind to the biomolecule.

8. A method for purifying a biomolecule, comprising isolating the biomolecule from a culture medium or complex matrix using a protein nanoparticle described in claim 1 that binds to the biomolecule.

9. 9. The method of claim 8, further comprising triggering phase separation of the binding polypeptides to isolate the biomolecule from contaminants, wherein the trigger is selected from adjusting temperature, salinity, light, pH, pressure, the concentration of the binding polypeptide or the concentration of the biomolecule, application of electromagnetic or acoustic waves, or addition of one or more excipients including one or more of a cofactor, a surfactant, a crowding reagent, a reducing agent, an oxidizing agent, a denaturant, or an enzyme. (a) the method further comprising: (i) separating the high density phase separated proteins bound to said biomolecules from contaminating biomolecules using centrifugation; (ii) using centrifugation to separate the phase-separated proteins bound to said biomolecules from contaminating biomolecules; or (iii) further comprising isolating the biomolecule from contaminant species using the size of the phase separation droplets, wherein the size of the binding polypeptide bound to the biomolecule is at least 20 nm and no more than 100 μm in diameter; or (b) the method comprises isolating the biomolecule-binding polypeptide complex from contaminant species based on size using flow filtration, membrane chromatography, analytical ultracentrifugation, high performance liquid chromatography, membrane chromatography, normal flow filtration, sonic separation, centrifugation, counterflow centrifugation, and fast protein liquid chromatography; or (c) The method of claim 9, wherein the biological molecule comprises at least one of a lipid, a cell, a protein, a nucleic acid, a carbohydrate, or a viral particle, the nucleic acid is single-stranded or double-stranded DNA or RNA, the viral particle is an adenovirus particle, an adeno-associated virus particle, a lentivirus particle, a retrovirus particle, a poxvirus particle, a measles virus particle, or a herpesvirus particle, and the protein is human albumin, a monoclonal IgG antibody, or an Fc fusion antibody.

11. A protein nanoparticle described in any one of claims 1 to 3, wherein the unstructured polypeptide is covalently crosslinked using a linker compatible with light or other click chemistry.

Images